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Large bone defects, such as those resulting from trauma or tumor resection, are 
currently repaired using autografts as the gold standard. However, major limitations of 
this therapeutic strategy, including restricted tissue availability and donor site morbidity, 
have necessitated the development of cell- and protein-based approaches. Cell-based 
bone tissue engineering strategies can enable localization of both an osteoprogenitor cell 
source and differentiation stimulus directly to the defect space. This reduced dependency 
on endogenous cell migration as well as the prospective benefit of delivered cell 
paracrine signaling position cell-based approaches as a promising alternative to the 
delivery of osteoinductive protein alone. However, challenges to control delivered cell 
behavior, including viability and differentiation, remain a significant barrier to clinical 
translation. 
Our research objectives were to evaluate a bioluminescent imaging (BLI) 
technique for the longitudinal monitoring of delivered mesenchymal stem cell (MSC) 
number and subsequently evaluate the effect of two MSC delivery strategies on cell 
survival and facilitated bone regeneration. Despite the widespread employment of BLI 
for tracking delivered cells in vivo, this technique had not yet been validated for large 
volume, multicomponent vehicles. To accomplish this goal, we developed and evaluated 
a BLI protocol using our alginate/mesh delivery platform implanted subcutaneously 
within an immunocompromised rat model. Correlation between BLI signal and viable 
MSC number was observed to persist through 1 week in vivo. While this work 
culminated in a powerful tool for subsequent studies, it also highlighted the potential role 
of confounding factors, including fibrotic and vascular tissue development, on BLI signal 
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correlation strength. Next we evaluated the utility of human platelet lysate (hPL), an 
enriched cytokine mixture, for the maintenance of delivered MSC viability and 
promotion of construct vasculature. Although hPL when implemented as either a pre-
treatment or co-delivery strategy had no influence on either outcome measure, limitations 
in the applicability of hPL pre-clinical testing via rodent testbeds, both 
immunocompromised and syngeneic, were identified through complementary in vitro 
analysis. 
Finally, we determined the effect of MSC aggregation, a strategy shown to 
enhance cell immunomodulatory properties, on delivered MSC survival and cell-based 
bone regeneration. Delivery of MSC spheroids was initially investigated within an 
immunocompromised rodent model (Nude rats) and found to have no effect on cell 
survival, construct vascularization, nor critically-sized bone defect repair. Interestingly, 
animal-to-animal variability within this model was found to be a significant predictor of 
cell-based bone regeneration, prompting the decision to conduct further studies within a 
syngeneic model. When examined within a syngeneic rodent model (Lewis rats), rMSC 
aggregates elicited a surviving cell fraction and construct vasculature comparable to that 
of single cell delivery. Despite in vitro observation that the osteoinductive potential of 
alginate/mesh constructs was increased with rMSC seeding, delivery of rMSC-containing 
treatments to the femoral defect space attenuated bone repair. In comparison to acellular 
treatment, regenerated bone volume and biomechanics were reduced with either single 
cell or aggregate delivery. 
The studies presented here explore two stem cell delivery strategies for large 
volume tissue regeneration. This research implemented a novel imaging platform to relate 
 xx 
key cell-based tissue regeneration metrics, namely delivered cell survival, construct 
vasculature, and functional outcomes, in an effort to elucidate fundamental principles for 
development of an effective MSC-based large bone defect therapeutic strategy. 
Importantly, this body of work also drew attention to several aspects of rodent model 
selection including xenogenicity, cross-reactivity, and biological variability. 
 
1 
CHAPTER 1  SPECIFIC AIMS 
   
Large bone defects, such as those resulting from trauma or tumor resection, are 
repaired using graft tissue as the current gold standard. However, limitations of this 
treatment approach, including limited tissue availability and poor revascularization post-
grafting, have motivated the development of cell- and protein-based strategies. 
Recombinant human bone morphogenetic protein-2 (BMP-2) is an FDA-approved 
osteoinductive protein clinically utilized to promote bone repair in incidences of non-
union. However, supra-physiologic dosing of BMP-2, as is often required for the repair of 
critically-sized defects, can result in adverse effects including heterotopic bone formation 
and systemic inflammation. 
 Cell-based bone tissue engineering strategies offer several potential advantages 
over the use of osteoinductive protein alone. The co-delivery of stem cells and BMP-2 
localizes both an osteoprogenitor cell source and differentiation stimulus directly to the 
defect space, thereby lessening the reliance on an individual’s endogenous repair capacity 
compared to equivalent acellular approaches. Furthermore, implanted stem cells may 
promote bone repair indirectly via paracrine signaling to host cell populations.  
Despite the promise of cell-based therapeutics for volumetric tissue regeneration, 
their present efficacy is challenged by poor integration and early death of delivered cells 
upon implantation. Irrespective of therapeutic mechanism, delivery strategies capable of 
maintaining stem cell viability following implantation are likely to improve regenerative 
outcome. Therefore, delivery strategies serving to enhance cell-based bone repair could 
act through, but are not limited to, an increase in implanted cell viability. 
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The overall objectives of this thesis were to (1) develop and validate a 
bioluminescent cell tracking protocol and (2) investigate stem cell delivery strategies to 
enhance viability and bone regeneration. The central hypotheses were that platelet lysate 
(PL) utilization and cell aggregation would better maintain delivered cell viability and 
improve cell-based bone regeneration. To this end, we proposed the following Specific 
Aims: 
 
Aim I: Develop a bioluminescence imaging (BLI) protocol for tracking 
mesenchymal stem cells (MSCs) within large hydrogel constructs in vivo.1 BLI 
enables the non-invasive and longitudinal monitoring of viable cells labeled for 
constitutive luciferase reporter protein expression. However, a host of exterior variables, 
including sample positioning, method of luciferin delivery, and tissue development, 
impact BLI measurement of a 3D system. We hypothesized that BLI could be used to 
quantify viable MSC number through 1 week in vivo. Within this aim, we sought to 
develop and validate a BLI protocol capable of monitoring MSCs delivered within large, 
multicomponent delivery constructs and investigate the influence of potentially 
confounding factors.  
 
Aim II: Evaluate the effects of platelet lysate (PL) pre-treatment and incorporation 
on hydrogel-embedded MSCs in vitro and in vivo. Human PL is an enriched cytokine 
mixture shown to enhance the expansion of MSCs in 2D by promoting increased 
                                                
 
 
1 Allen, AB; Gazit, Z, Su, S; Stevens, HY; Guldberg, RE; In Vivo Bioluminescent Tracking of 
Mesenchymal Stem Cells within Large Hydrogel Constructs. Tissue Engineering Part C Methods (2014) 
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proliferation and preserving stem cell phenotype. We hypothesized that the utilization of 
hPL would better maintain hMSC viability and enhance vascular ingrowth in vivo. This 
work examined the impact of hPL expansion, construct pre-culture, and co-delivery on 
viable hMSC retention following implantation within large, multicomponent constructs. 
In pursuing these studies, we further hypothesized that rodent models for hPL pre-clinical 
testing would be limited by issues of xenogenicity and species variability.  
 
Aim III: Quantify the effects of MSC aggregation on cell survival and large bone 
defect repair. MSC aggregation has been shown to inhibit cell apoptosis as well as 
enhance cell angiogenic and anti-inflammatory properties. We hypothesized that MSC 
aggregation would improve cell survival in vivo. The impact of aggregation on viable 
MSC retention was evaluated within a subcutaneous implantation model and 
subsequently challenged for bone repair within a critically-sized femoral defect. As bone 
regeneration is a process finely tuned to its local inflammatory environment, we further 
hypothesized that the delivery of MSC aggregates would enhance large bone defect 
repair in comparison to single cell or acellular approaches. 
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CHAPTER 2  LITERATURE REVIEW 
 
2.1 Introduction to Bone Tissue and Repair 
2.1.1 Bone Function and Composition 
Our skeleton provides the structural framework for other organs in the body. Bone 
tissue behaves viscoelastically, achieving tensile strength and mechanical stability due to 
a mix of organic and inorganic components (Boskey and Posner 1984, Buckwalter and 
Cooper 1987). Bone is anisotropic with the greatest elastic modulus being in the 
longitudinal direction and able to withstand the highest magnitude of stress in 
compression (Novitskaya, Chen et al. 2011). In addition to this structural purpose, bones 
serve the critical function of maintaining calcium and phosphate homeostasis in the body 
through regulated resorption and regeneration of the bone matrix (Yates, Gutierrez et al. 
1988). Furthermore, bone marrow, as the environment in which hematopoiesis occurs, 
represents a key component of the immune system (Morrison and Scadden 2014). 
Bone is a matrix comprised of organic and inorganic constituents. The primary 
organic component is a glycoprotein called type I collagen and the dominant inorganic 
component is calcium hydroxyapatite (Buckwalter and Cooper 1987). These entities 
make up two types of tissue within the bone: cortical and trabecular (Buckwalter and 
Cooper 1987). Cortical tissue is the hard and dense outer layer of bone while trabecular 
tissue is the porous structure within the interior. Trabecular bone consists of strut-like 
bone elements surrounded by blood and marrow. Trabeculae quantity and orientation are 
influenced by several factors, including qualities of the individual (e.g. gender, age, 
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activity levels, and diet) and function of a particular bone segment, and impact the 
mechanical properties of bone (Wolfram, Wilke et al. 2010).  
The bone matrix is formed and remodeled by predominantly three bone cell types: 
osteoblasts, osteocytes and osteoclasts (Buckwalter and Cooper 1987). Osteoblasts are 
bone forming cells that differentiate into osteocytes upon entrapment within the bone 
matrix (Aarden, Burger et al. 1994). These cells secrete type I collagen in addition to 
other proteins (e.g. fibronectin, osteopontin, and osteocalcin) that make up the organic 
matrix as well as mediate bone mineralization (Marotti 1996). Mineralization acts via 
increased alkaline phosphatase (ALP) activity that furthers organic phosphate levels in 
the cell vicinity, culminating in the growth and deposition of hydroxyapatite onto 
collagen fibers within the bone matrix (Boskey and Posner 1984). Osteocytes are located 
within osteon structures consisting of concentric lacunae rings surrounding a single 
Haversian canal (Metz, Martin et al. 2003). Canaliculi extend from each osteocyte for the 
purpose of nutrient and waste exchange. This exchange occurs ultimately by way of the 
Haversian canals as these run parallel to the long axis of the bone and surround the nerves 
and blood vessels which are necessary to provide sensory and biochemical input to the 
bone tissue (Metz, Martin et al. 2003). Finally, osteoclasts are bone resorbing cells which 
allow for release of calcium and phosphate in response to growth factor or cytokine 
stimuli (Suda, Nakamura et al. 1997).  
2.1.2 Bone Remodeling 
 Bone remodeling is governed by both mechanical and biochemical cues. 
Mechanically induced stimuli include the responsiveness of osteocytes and bone lining 
cells to strain, piezoelectric effects, and fluid flow (Vaananen, Zhao et al. 2000, You, 
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Temiyasathit et al. 2008). Biochemical signaling, either the consequence of 
mechanotransduction or arising independently, acts through a range of mechanisms as 
well. Nitric oxide and prostaglandins serve as signaling molecules to stimulate or inhibit 
activity of the osteoblast and osteoclast effector cells (Wimalawansa 2010). The soluble 
factors osteoprotegrin (OPG) and receptor activator of nuclear factor kappa-B ligand 
(RANKL) play a role in bone remodeling through regulation of osteoclastogenesis (Blair, 
Zhou et al. 2006). OPG acts as a decoy receptor for RANKL and thereby decreases the 
quantity available to activate osteoclast precursor cells through binding of their RANK 
receptor. In the event of activation, precursor cells enlarge and fuse in order to form 
mature osteoclasts, which subsequently dissolve hydroxyapatite matrix through formation 
of resorption pits on the bone surface (Blair, Zhou et al. 2006). 
 A myriad of soluble factors and signaling cascades play a role in bone 
homeostasis. The canonical Wnt pathway acts through increased accumulation of β–
catenin to up-regulate Rux2 expression (Lodewyckx and Lories 2009). Runx2 induces 
ALP activity and expression of bone matrix proteins, resulting in osteoblastogenesis and 
down-regulated osteoclast differentiation through inhibition of RANKL. Other major 
contributors to bone mass increase are members of the transforming growth factor beta 
(TGF-β) superfamily known as bone morphogenetic proteins (BMPs) (Moustakas and 
Heldin 2005). These act through BMP receptors on the cell surface, activating the smad 
signaling cascade and promoting osteoblastic differentiation (Nishimura, Hata et al. 
2003). Numerous negative feedback mechanisms are present in bone tissue such that 
resorption and repair are coupled (Jones, Gray et al. 1994). In the late stage of 
development, osteocytes secrete the protein sclerostin which acts through the inhibition 
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of BMP activity to prevent downstream gene expression and subsequent increase in bone 
mass (Poole, van Bezooijen et al. 2005). Reciprocally, resorption of bone matrix releases 
insulin-like growth factor (IGF) and TGF-β growth factors that promote bone formation 
by increasing osteoblast number and activity (Crane and Cao 2014). The endocrine 
system plays a role in bone mass control and remodeling as well including signaling via 
estrogen, androgens, and growth hormone (Parfitt 1976, Dobnig, Kainer et al. 1995).  
2.1.3 Bone Fracture and Repair 
 In the event of injury to long bones, normal fracture healing is accomplished via 
progression through phases of hematoma, inflammation, callus formation, and eventual 
remodeling (McKibbin 1978, Gaston and Simpson 2007, Bahney, Hu et al. 2015). 
Initiation of tissue regeneration occurs concomitantly with the infiltration of 
inflammatory cells, beginning with neutrophils and macrophages sequentially (Bastian, 
Pillay et al. 2011). In circumstances progressing to tissue repair, resolution of this acute 
inflammatory stage affords an environment permissive to ossification via 
intramembranous or endochondral pathways (Colnot 2009). In the case of endochondral 
ossification, progenitor cells undergo chondrogenesis and hypertrophic maturation, 
serving to establish a calcified cartilage matrix that is ultimately replaced by bone (Roach 
1992, Kronenberg 2003). 
 Many factors influence the inflammatory environment of regenerating bone tissue 
and thereby play a role in repair efficacy (Mountziaris, Spicer et al. 2011, Thomas and 
Puleo 2011). These include arachidonic acid metabolites (e.g. prostaglandin E2 (PGE2)), 
cytokines (e.g. tumor necrosis factor alpha (TNF-α) and interleukins), and growth factors 
(e.g. BMP-2, vascular endothelial growth factor (VEGF), and platelet-derived growth 
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factor (PDGF)) (Caplan and Correa 2011, Thomas and Puleo 2011, Bahney, Hu et al. 
2015). Interestingly, several of these inflammatory mediators promote both regenerative 
and resorptive events (Mountziaris, Spicer et al. 2011, Thomas and Puleo 2011). 
Although interleukin 6 (IL-6) promotes osteoclastogenesis, this chemoattractant also 
furthers bone healing acting as a mediator of macrophage recruitment and has been 
identified as a requisite for fracture callus maturation (Gorny, Shaw et al. 2004, Yang, 
Ricciardi et al. 2007, Bastian, Pillay et al. 2011). Adding to an already multifaceted 
progression of inflammatory processes, resident bone cells (e.g. osetoblasts and 
chondrocytes), rather than those of the immune system, are shown to be the chief source 
of inflammatory cytokines following acute regenerative events (Kon, Cho et al. 2001, 
Mountziaris, Spicer et al. 2011). Ultimately, a great body of work has exposed the 
temporal and complex nature of bone tissue repair via orchestrated inflammatory 
processes (Gerstenfeld, Cho et al. 2003, Schmidt-Bleek, Schell et al. 2012, Kovach, 
Dighe et al. 2015). 
2.1.4 Non-Healing Bone Defects 
 Despite the notable ability of bone tissue to regenerate and remodel, cases of non-
union present a significant clinical challenge and occur in instances of large bone defects 
or approximately 5-10% of fractures (Johnson, Urist et al. 1992, Calori, Albisetti et al. 
2007, Tzioupis and Giannoudis 2007, Hollinger, Hart et al. 2008, Calori, Mazza et al. 
2011). Large bone defects exceeding a length of 3 cm in the forearm or 6 cm in the femur 
represent a significant clinical challenge, as ingrowth of soft tissue at the defect site can 
lead to eventual non-union (Calori, Mazza et al. 2011, Zhang, Teoh et al. 2012). These 
critically-sized injuries can arise from incidences of trauma or bone resection (for 
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example, in the case of tumor or infection) and will lead to non-union without therapeutic 
intervention (Johnson, Urist et al. 1992). The current gold standard to treat or prevent 
non-union is grafting of autologous bone tissue to the defect site and it is estimated that 
1.5 million of such operations take place in the United States annually (Einhorn 2003, 
Jones, Bucholz et al. 2006, Calori, Mazza et al. 2011). However, use of autografts has 
several disadvantages that preclude its utility for large bone defect treatment, including 
limited tissue availability, donor-site morbidity, and prolonged surgical time (Younger 
and Chapman 1989, Banwart, Asher et al. 1995, Goulet, Senunas et al. 1997, St John, 
Vaccaro et al. 2003). Allografts are a plausible alternative, but have shown difficulty re-
vascularizing upon implantation and can experience subsequent fracture (Berrey, Lord et 
al. 1990, Finkemeier 2002, Kim, Kang et al. 2010). 
 Limitations of grafting techniques have motivated the development of cell- and 
protein-based approaches. Bone morphogenetic proteins were first identified as 
osteoinductive factors in the 1980s and today human recombinant bone morphogenetic 
proteins 2 (rhBMP-2) and 7 (rhBMP-7) are both clinically-approved for delivery using an 
absorbable collagen sponge (Wang, Rosen et al. 1988, Wozney, Rosen et al. 1988, 
Gautschi, Frey et al. 2007, Bessa, Casal et al. 2008). While patient treatment has been 
successful in many instances, overall efficacy of BMP delivery is lower than that seen in 
pre-clinical animal studies (Einhorn 2003). Recent research has focused on tailoring BMP 
release kinetics through the implementation of novel deliver systems (Seeherman, 
Wozney et al. 2002, Termaat, Den Boer et al. 2005, Ripamonti, Heliotis et al. 2007, 
Bessa, Casal et al. 2008, Boerckel, Kolambkar et al. 2011, Priddy, Chaudhuri et al. 2014, 
Shekaran, Garcia et al. 2014).  
 10 
2.1.5 Stem Cell Delivery for Bone Repair 
 Cell-based bone regeneration approaches have many potential advantages over 
the presentation of osteoinductive cue alone. Acellular approaches rely on the infiltration 
and subsequent osteogenic differentiation of host cells in the defect space (Perry 1999, 
Hutmacher 2000, Hutmacher, Schantz et al. 2007, Calori, Mazza et al. 2011). However, 
in instances where patients are aged, have undergone radiation therapy, or have an 
adjacent soft tissue injury, availability of these endogenous cell populations is 
compromised (Bruder and Fox 1999, Service 2000, Fehrer and Lepperdinger 2005, Sethe, 
Scutt et al. 2006, Caplan 2007, Cao, Luo et al. 2011). Additionally, the co-delivery of 
cells with an osteoinductive factor, such as rhBMP-2 or rhBMP-7, may enable use of a 
lower protein dose in order to produce similar efficacy. Several adverse effects, including 
ectopic mineralization, inflammation, and bone resorption, have been observed when 
delivering rhBMP-2 at high doses (Hollinger, Brekke et al. 1996, Marsh and Li 1999, 
Poynton and Lane 2002, Shields, Raque et al. 2006, Smucker, Rhee et al. 2006, 
Giannoudis, Einhorn et al. 2007, Perri, Cooper et al. 2007, Benglis, Wang et al. 2008, 
Lee, Taghavi et al. 2012). 
 Delivered stem cells have the capacity to contribute both directly and indirectly to 
bone formation (Waese, Kandel et al. 2008, Maraldi, Riccio et al. 2011). Implanted cells 
can indirectly enhance bone repair either via an inherent or engineered secretome. 
Embryonic, adult, and fetal stem cell sources have each demonstrated the ability to 
modulate the angiogenic response in vivo (Mirabella, Cilli et al. 2011, Rustad, Wong et 
al. 2012). Furthermore, cell delivery can enable the presentation of osteoinductive factor 
via genetic engineering, a strategy that has shown efficacy by several research groups 
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(Lieberman, Daluiski et al. 1999, Lou, Xu et al. 1999, Parikh 2002, Jin, Anusaksathien et 
al. 2003, Wang, Kanim et al. 2003, Gafni, Pelled et al. 2004, Termaat, Den Boer et al. 
2005, Kim, Kang et al. 2010, Mumaw, Jordan et al. 2012). 
 
2.2 Mesenchymal Stem Cell (MSC) Delivery for Large Bone Defect Repair 
2.2.1 MSC Isolation and Properties 
 Human mesenchymal stem cells (hMSCs) were first isolated from bone marrow 
tissue in the 1960s and have since been identified within a variety of additional tissues 
including periosteum, skeletal muscle, fat, and other postnatal tissues (Friedenstein, 
Piatetzky et al. 1966, Barry and Murphy 2004, da Silva Meirelles, Chagastelles et al. 
2006). MSCs have also been isolated from a variety of fetal tissues and animal species 
(Campagnoli, Roberts et al. 2001, In 't Anker, Scherjon et al. 2003, Meirelles Lda and 
Nardi 2003, Bieback, Kern et al. 2004, Sarugaser, Lickorish et al. 2005, Carrade and 
Borjesson 2013). Traditionally, MSCs have been characterized by their multipotency: an 
ability to differentiate into bone, cartilage, and fat (Owen and Friedenstein 1988, Caplan 
1991, Prockop 1997, De Bari, Dell'Accio et al. 2003, De Ugarte, Morizono et al. 2003, 
Kim, Kang et al. 2010). Subsequent work has found they may be capable of 
differentiating into muscle, ligament, neuronal, and cardiac cells as well (Wakitani, Saito 
et al. 1995, Kopen, Prockop et al. 1999, Banfi, Muraglia et al. 2000, Woodbury, Schwarz 
et al. 2000, Toma, Pittenger et al. 2002, Kawada, Fujita et al. 2004, Kostura, Kraitchman 
et al. 2004, Monaco, Bionaz et al. 2012). The multipotent capacity and phenotype of 
MSCs is similar and potentially identical to pericyte cells; however, assertion of their 
equivalence has been difficult to prove (da Silva Meirelles, Caplan et al. 2008, Caplan 
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2009, Caplan and Correa 2011, Zhang, Teoh et al. 2012). In vitro hMSCs have also been 
characterized according to immunophenotype, showing positive expression of CD105, 
CD73 and CD90 and absence of CD34, CD45, and HLA-II (Barry and Murphy 2004, 
Dominici, Le Blanc et al. 2006, Mamidi, Nathan et al. 2012, Qian, Le Blanc et al. 2012, 
Zhang, Teoh et al. 2012). Although MSCs constitute a small proportion of the nucleated 
cells in bone marrow (0.001-0.01%), their ease of isolation and culture expansion have 
made them a promising candidate for tissue engineering applications (Simmons and 
Torok-Storb 1991, Pittenger, Mackay et al. 1999, Banfi, Muraglia et al. 2000, Lodie, 
Blickarz et al. 2002, Sawada, Ito et al. 2006, Aguilar, Nye et al. 2007, Bernardo, 
Zaffaroni et al. 2007, Meza-Zepeda, Noer et al. 2008). However, MSCs exhibit reduced 
expansion efficiency and the ability to differentiate along multiple lineages over time in 
fetal bovine serum (FBS)-supplemented culture, implying that obtainable cell yield and 
applications for autologous therapies are limited (Banfi, Muraglia et al. 2000, Wagner, 
Horn et al. 2008, Ben Azouna, Jenhani et al. 2012). 
 MSCs have been investigated for therapeutic potential using both local and 
systemic delivery methods (Banfi, Muraglia et al. 2000, Mauney, Volloch et al. 2005). 
They have been examined for a range of applications, including orthopedic, 
cardiovascular, graft-versus-host disease, and spinal cord injury treatment, and have been 
featured in hundreds of clinical trials (Barry and Murphy 2004, Haack-Sorensen, Hansen 
et al. 2012, Zhang, Teoh et al. 2012). Several studies have illustrated the ability of MSCs 
to promote angiogenesis through paracrine signaling (Bhang, Lee et al. 2012, Osugi, 
Katagiri et al. 2012, Rustad, Wong et al. 2012, Schlosser, Dennler et al. 2012).  MSCs 
have a degree of immune privilege due to lack of HLA Class II expression and their 
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ability to modulate T cell proliferation and phenotype (Moretta, Bottino et al. 2001, 
Bartholomew, Sturgeon et al. 2002, Aggarwal and Pittenger 2005, Ren, Su et al. 2009, 
De Miguel, Fuentes-Julian et al. 2012). When delivered systemically, MSCs have proven 
capable of homing to sites of injury (Mackenzie and Flake 2001, Bittira, Shum-Tim et al. 
2003). 
2.2.2 MSC Delivery for Bone Regeneration 
 The utility of MSC delivery for bone repair has been investigated in a range of 
studies (Aggarwal and Pittenger 2005, Kim, Kang et al. 2010, Ciapetti, Granchi et al. 
2012). hMSCs can facilitate surface (2D) and scaffold (3D) mineralization when 
osteogenically differentiated in vitro (Kolambkar, Peister et al. 2010, Jones and Yang 
2011, Peister, Woodruff et al. 2011). Furthermore, MSC delivery in vivo can augment 
both fracture and large bone defect repair (Kadiyala, Young et al. 1997, Quarto, 
Mastrogiacomo et al. 2001, Dallari, Fini et al. 2006, Nather, David et al. 2010, Jones and 
Yang 2011, Cao, Liu et al. 2012, Dupont, Boerckel et al. 2012, Zhang, Teoh et al. 2012, 
Dosier, Uhrig et al. 2015). However, despite some promising experimental results, 
development of a reliable MSC-based bone repair strategy is plagued by considerable 
difficulties and slow clinical translation (Bruder, Jaiswal et al. 1998, Janicki and 
Schmidmaier 2011, Osugi, Katagiri et al. 2012). Delivered MSCs exhibit poor long-term 
engraftment rates and optimal design criteria, such as MSC tissue source, cell dose, 
delivery timeline, and scaffold selection, are still not established (Freyman, Polin et al. 
2006, Newcomb, Ajmo et al. 2006, Olivo, Alblas et al. 2008, Waese, Kandel et al. 2008, 
Ide, Nakai et al. 2010, Grieshaber, Nie et al. 2011, Burdick 2012, Kim, Shin et al. 2012, 
Monaco, Bionaz et al. 2012, Rustad, Wong et al. 2012, Dosier, Uhrig et al. 2015). Donor-
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to-donor variability, lack of information regarding cell fate, and dissimilarity of pre-
treatment and delivery strategies employed across the field, challenge the establishment 
of a potent and predictable MSC-based therapeutic (Barry and Murphy 2004, Pelled and 
Gazit 2004, de Boer, van Blitterswijk et al. 2006, Janicki and Schmidmaier 2011, Yew, 
Huang et al. 2012, Zhang, Teoh et al. 2012). 
Discussing volumetric tissue regeneration more broadly, efforts to develop cell-
based therapeutics have been challenged by poor integration and early death of delivered 
cells upon implantation (Tasso, Augello et al. 2009, Giannoni, Scaglione et al. 2010). 
Endogenous cells are typically situated within 200 µm of a vascular network and rely on 
diffusion for their nutrient and oxygen supplies (Lovett, Lee et al. 2009). Cells implanted 
within tissue engineering constructs, however, in the absence of pre-vascularized 
networks, may initially experience physiologically abnormal oxygen tension and reduced 
transport of nutrients and waste to and from the implantation site (Muschler, Nakamoto et 
al. 2004, Becquart, Cambon-Binder et al. 2012).  
2.2.3 In Vivo MSC Tracking Strategies 
 Given the challenge of and focus on better maintaining MSC viability post-
implantation, several tools have emerged to enable the monitoring of delivered cells. 
Non-invasive cell tracking strategies include bioluminescence, fluorescence, and 
magnetic resonance imaging (MRI) (Bulte, Douglas et al. 2002, Arbab, Bashaw et al. 
2003, Jager, Michalet et al. 2005, Mook, Jonker et al. 2008). However, techniques that 
rely on the monitoring of cell-contained particles are limited in their utility for longer 
durations in vivo. For example, particles may be phagocytized upon cell death, leading to 
the tracking of host macrophages (Terrovitis, Stuber et al. 2008, Dupont, Sharma et al. 
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2010, Vreys, Soenen et al. 2011). Furthermore, although particle-based labels are 
conferred to daughter cells upon proliferation, per cell signal magnitude is altered 
(Alivisatos, Gu et al. 2005, Walczak, Kedziorek et al. 2007, Taylor, Wilson et al. 2012). 
This limitation disrupts the ability to detect cell number increase, of particular importance 
when tracking rapidly dividing stem cells. In contrast, bioluminescent imaging (BLI) is 
contingent on expression of a reporter gene that has been inserted into the delivered cell 
genome, thereby monitoring specifically the viable cell population of interest as signal is 
tied exclusively to labeled cell viability and passed through genetic code upon cell 
division (Zhang and Wu 2007).  
 BLI measures photons released from the luciferase-catalyzed oxidation of D-
luciferin substrate and uses this metric as an indicator of luciferase gene expression from 
genetically-modified cells (Herschman 2004, de Boer, van Blitterswijk et al. 2006, 
Ottobrini, Martelli et al. 2011). Although BLI is largely used to monitor cell number, 
placement of luciferase expression under control of a non-constitutive promoter 
facilitates detection of delivered cell function, such as the differentiation of an implanted 
stem cell (Sheyn, Kallai et al. 2011, Oh, Hwang et al. 2013). Due to its collective 
advantages over alternate tracking strategies, BLI has become an invaluable optical 
imaging technique for the development of cancer therapies and regenerative medicine 
strategies within experimental models (O'Neill, Lyons et al. 2010, de Almeida, van 
Rappard et al. 2011). Several groups have used BLI to track the spatial and temporal 
behavior of implanted cells for development of cell-based therapeutics (Hara, Murakami 
et al. 2008, Sacco, Doyonnas et al. 2008, Wang, Cao et al. 2009, Sheyn, Kallai et al. 
2011). The ability to monitor luciferase-labeled cell viability in vivo through 6-7 weeks 
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has been demonstrated in several studies (Olivo, Alblas et al. 2008, Geuze, Prins et al. 
2010). For these experiments, cells have typically been delivered using a relatively small 
vehicle volume (less than 75mm3) with administration of luciferin substrate via 
intraperitoneal (IP) injection (Olivo, Alblas et al. 2008, Wang, Cao et al. 2009, Geuze, 
Prins et al. 2010). However, in the case of larger constructs with increased transport 
limitations, development of an appropriate BLI protocol presents a more substantial 
challenge (Miki, Hirose et al. 2009). BLI signal is dependent on variables including 
construct composition, luciferin delivery method, animal model, sample positioning, and 
progression of tissue development in vivo (de Boer, van Blitterswijk et al. 2006, Inoue, 
Kiryu et al. 2010, O'Neill, Lyons et al. 2010, Liu, Hilderink et al. 2013). Thus, validation 
of imaging technique within each experimental system is necessary to ensure an accurate 
live cell representation.  
 
2.3 Human Platelet Lysate 
2.3.1 Platelet-Rich Plasma 
 Platelet-rich plasma (PRP) is a blood-derived product that is clinically approved 
for autologous therapy and has been used in a variety of wound-healing and tissue repair 
applications, including in sports medicine, plastic surgery, and bone regeneration (Dohan 
Ehrenfest, Rasmusson et al. 2009, Redler, Thompson et al. 2011). PRP is produced 
through separation of apheresis product to obtain plasma of a high platelet concentration 
and its delivery serves to localize supra-physiological levels of growth factors contained 
within the platelet α-granules (Feltsan, Mracna et al. 2011, Redler, Thompson et al. 
2011). Delivered proteins, including PDGF, VEGF, TGF-β, and IGF, are capable of 
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stimulating cell proliferation, extracellular matrix production, and angiogenesis at the site 
of injury (Filvaroff 2003, Anitua, Andia et al. 2004, El-Sharkawy, Kantarci et al. 2007, 
Keramaris, Calori et al. 2008, Beamer, Hettrich et al. 2010, Feltsan, Mracna et al. 2011, 
Anitua and Orive 2012). These factors have also been shown to impact bone regeneration 
and remodeling, thus several studies have investigated the utility of PRP for bone defect 
treatment (Ross, Raines et al. 1986, Canalis 1993, Roberts 1995, Marx, Carlson et al. 
1998, Keramaris, Calori et al. 2008). Investigators have found PRP to contribute 
positively to bone regeneration in instances where it has been co-delivered with stem 
cells or an osteogenic stimulus (Berner, Boerckel et al. 2012, Monteiro, Del Carlo et al. 
2012, Zhong, Sumita et al. 2012). However, efficacy of PRP treatment has been variable, 
likely due to differences in product composition arising from variations between 
apheresis donor, preparation protocol, and platelet activation strategy (Dohan Ehrenfest, 
Rasmusson et al. 2009, Macher, Sipurzynski-Budrass et al. 2010, Redler, Thompson et al. 
2011).  
2.3.2 Production and Characteristics of Human Platelet Lysate 
 Although PRP has a shelf-life of only five days, platelets have been shown to 
retain their growth factor activity through several weeks (Chan, Liu et al. 2005, Rauch, 
Feifel et al. 2011). Expired PRP can be taken through a series of freeze-thaw cycles, 
filtered, and combined with that of additional donors to generate pooled human platelet 
lysate (hPL), a solution retaining growth factor stability over several months of storage 
(Doucet, Ernou et al. 2005, Schallmoser, Bartmann et al. 2007, Rauch, Feifel et al. 2011, 
Lohmann, Walenda et al. 2012). hPL is an enriched growth factor mixture, containing 
PDGF, VEGF, latent TGF-β, IGF, basic fibroblast growth factor (bFGF), and epidermal 
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growth factor (EGF) (Reed, Fitzgerald et al. 2000, Rendu and Brohard-Bohn 2001, King 
and Reed 2002, Maguire and Fitzgerald 2003, Lohmann, Walenda et al. 2012). hPL has 
several advantages over PRP, including greater consistency in its composition and the 
ability to be administered as an allogeneic therapeutic. Donor-to-donor and cell content 
variability are lessened for hPL due to the fact that several donors are pooled and residual 
cell membrane and platelet body components are filtered (Rauch, Feifel et al. 2011, 
Lohmann, Walenda et al. 2012). This removal of antigen-containing components along 
with the capacity to conduct multiple rounds of donor testing prior to utilization, made 
possible by the extended shelf-life, allow hPL to be used allogeneically with reduced 
safety concern (Schallmoser, Bartmann et al. 2007).  
2.3.3 hPL for hMSC Culture 
 The fibrinogen content of hPL allows it to be present either in a coagulated gel 
form or, through methods of fibrinogen depletion or anticoagulant addition, as a liquid 
(Harrison and Cramer 1993, Walenda, Hemeda et al. 2012). However, hPL has 
predominantly been explored in its liquid form as a substitute to fetal bovine serum (FBS) 
for cell culture expansion (Doucet, Ernou et al. 2005, Schallmoser, Bartmann et al. 2007, 
Bernardo, Cometa et al. 2011). In addition to eliminating the risks of xenogenic immune 
response and bovine virus transmission associated with FBS culture, hPL-supplemented 
media has been shown to enhance cell proliferation and colony-forming unit (CFU) size 
(Muller, Kordowich et al. 2006, Bernardo, Avanzini et al. 2007, Reinisch, Bartmann et al. 
2007, Carrancio, Lopez-Holgado et al. 2008). Furthermore, the immunophenotype, 
differentiation capacity, and immunomodulatory properties of hMSCs cultured in hPL-
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supplemented media remain unaltered (Doucet, Ernou et al. 2005, Schallmoser, Bartmann 
et al. 2007, Azouna, Berraeis et al. 2011, Flemming, Schallmoser et al. 2011). 
2.3.4 hPL for Bone Tissue Engineering 
 While hPL does not directly stimulate bone formation, several studies have 
identified its role as an “osteopromoter” (De Long, Einhorn et al. 2007). PDGF, a major 
component of hPL, has been shown to be a potent mitogen in all three dimer forms (Hart, 
Bailey et al. 1990, Anitua and Orive 2012). Additionally, PDGF-BB is a chemoattractive 
agent and has the capacity to modulate both bone and vascular remodeling in vivo 
through its promotion of pericyte release (Caplan and Correa 2011). Heightened pericyte 
release activity leads to an increase in MSC and osteoprogenitor cell availability that can 
enhance local bone formation (Caplan 2005, Caplan 2009, Caplan and Correa 2011). 
Recombinant human PDGF-BB (rhPDGF-BB) is clinically approved and has consistently 
demonstrated an ability to enhance bone regeneration when co-delivered with β-
tricalcium phosphate matrix for treatment of orthopaedic injuries (Hollinger, Hart et al. 
2008). Although the impact of hPL-supplemented media on in vitro osteogenic 
differentiation has been well explored, the utility of hPL as a matrix component for bone 
regeneration has been minimally studied (Schallmoser, Bartmann et al. 2007, Santo, 
Duarte et al. 2012). Results from Dozza et al. found that co-delivery of platelet lysate and 
MSCs promoted femoral prosthesis integration in comparison to the treatment of 
prosthesis alone; however, from this study, one cannot conclude whether this 
enhancement was due to the lysate or cellular component (Dozza, Chiari et al. 2011). 
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2.4 MSC Aggregation 
2.4.1 Introduction to Cell Aggregates 
 Mammalian cell aggregation has been performed on a variety of cell types, 
including pluripotent, multipotent, and differentiated, for a wide range of objectives such 
as hepatic culture, tumor and microgravity models, drug development, facilitated 3D 
printing, and cell differentiation (Wartenberg, Donmez et al. 2001, Boland, Mironov et al. 
2003, Kunz-Schughart, Freyer et al. 2004, Fukuda, Sakai et al. 2006, Ulbrich, Wehland et 
al. 2014, Toyoda, Mae et al. 2015). Aggregates can be formed through a variety of 
methods including micro-wells, hanging drops, and microfluidic culture systems 
(Torisawa, Takagi et al. 2007, Bartosh, Ylostalo et al. 2010). Such approaches have been 
used to form aggregates ranging in size (50–1200 µm diameter) and cell number (200–
250,000 cells/spheroid) (Torisawa, Takagi et al. 2007, Bartosh, Ylostalo et al. 2010, 
Ulbrich, Wehland et al. 2014, Zimmermann and McDevitt 2014). 
2.4.2 Characterization of MSC Aggregates 
 To a certain extent, the properties of aggregated MSCs vary as a function of 
culture conditions. Metabolic activity and apoptosis are found to be dependent on 
spheroid size in an inverse and proportional manner, respectively (Murphy, Fang et al. 
2014). Change in aggregated cell number over time in culture is a function of variables 
including spheroid size as well as media composition (Murphy, Fang et al. 2014, 
Zimmermann and McDevitt 2014). However, despite heterogeneity in the response of 
MSCs to spheroid culture, several therapeutic benefits of this approach have been 
identified and corroborated in the field. Multiple studies have identified an improvement 
in angiogenic properties with aggregation. Up-regulated VEGF secretion has been 
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observed for MSC spheroids in suspension or encapsulated within hydrogels cultured in 
vitro (Lee, Park et al. 2012, Murphy, Fang et al. 2014). Delivery of aggregates to 
ischemic tissue has improved cell grafting, vasculature, and regenerative outcome (Wang, 
Chen et al. 2009, Bhang, Cho et al. 2011, Lee, Park et al. 2012). Aggregation may also 
have therapeutic potential for cancer treatment, as spheroid MSCs increased production 
of chemokine receptor 4 (CXCR4) and interleukin 24 (IL-24), factors involved in MSC 
homing and tumor suppression (Potapova, Brink et al. 2008, Bartosh, Ylostalo et al. 
2010, Frith, Thomson et al. 2010). 
 Of particular interest to cell-based bone regeneration strategies are the effects of 
aggregation on MSC immunomodulatory secretome and osteogenic differentiation 
capacity. Aggregation improves the efficiency of MSC differentiation down adipogenic 
or osteogenic lineage through a combination of up-regulated differentiation genes and 
down-regulated genes governing self-renewal phenotype (Wang, Itaka et al. 2009, Frith, 
Thomson et al. 2010, Murphy, Fang et al. 2014, Yamaguchi, Ohno et al. 2014). 
Furthermore, expression of dickkopf 1 (Dkk-1), an inhibitor of Wnt signaling, has been 
observed to decrease with aggregate culture in the absence of a differentiation stimulus 
(Bartosh, Ylostalo et al. 2010, Frith, Thomson et al. 2010). When challenged in vivo, 
delivery of MSC spheroids to an orthotopic bone defect promoted healing over that of 
single cells or vehicle alone (Yamaguchi, Ohno et al. 2014). This bone repair efficacy 
could be due to the superior differentiation or paracrine signaling capacity of MSC 
spheroids, as cell immunomodulatory properties are altered with aggregation as well. 
Spheroid culture increased production of immunomodulatory factors, including tumor 
necrosis factor-inducible gene 6 protein (TSG-6), indoleamine 2,3-dioxygenase (IDO), 
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IL-6, and PGE2, in comparison to MSCs cultured in monolayer (Bartosh, Ylostalo et al. 
2010, Zimmermann and McDevitt 2014). Additionally, exposure of MSC spheroids to 
pro-inflammatory cytokines, as found within injured tissue, further enhanced this factor 
secretion (Zimmermann and McDevitt 2014). MSC aggregate co-culture with stimulated 
macrophages decreased their expression of pro-inflammatory cytokines (Bartosh, 
Ylostalo et al. 2010). Upon delivery to a zymosan-induced peritonitis mouse model, 
intraperitoneal implantation of either aggregated or aggregate-derived MSCs decreased 
inflammation, with intact aggregates proving the more efficacious strategy (Bartosh, 
Ylostalo et al. 2010).  
 
2.5 Motivations for Research 
 Despite the promise of cell-based therapeutics for large bone defect repair, their 
potential as a clinically viable solution has not been realized. A major barrier to 
translational efficacy is the challenge to control delivered cell behavior, including 
viability, differentiation, and factor secretion. Efforts to engineer these properties 
inevitably fall short due to a fundamental lack of understanding about the relative 
influence of these parameters on each other as well as regenerative outcome. To add 
critical dialogue to this conversation, this thesis work explores two stem cell delivery 
strategies. hPL utilization and cell aggregation have each demonstrated the ability to 
impact a range of MSC outcomes, including cell number, phenotype, and secretome. 
However, neither strategy has been explored for developing an MSC-based solution to 
critically-sized bone defect repair. In addition to engineering an efficacious MSC-based 
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bone regeneration strategy, this research aimed to relate key principles influencing cell-
based tissue regeneration more globally. 
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CHAPTER 3  DEVELOPMENT OF AN IN VIVO 




Bioluminescent imaging (BLI) has emerged as a valuable tool for tracking cell 
populations in vivo (de Boer, van Blitterswijk et al. 2006, de Almeida, van Rappard et al. 
2011). By measuring photon release from the luciferase-catalyzed oxidation of luciferin 
substrate, BLI can non-invasively and longitudinally monitor the presence of viable cells 
labeled by means of constitutive luciferase reporter protein expression. Alternatively, by 
placing luciferase expression under the control of a non-constitutive promoter, BLI can 
follow delivered cell function, such as the differentiation of an implanted stem cell 
(Sheyn, Kallai et al. 2011, Oh, Hwang et al. 2013). 
In addition to luciferase quantity, several variables influence BLI measurement 
and can potentially impact its utility as an indicator of viable cell number. These 
variables include sample positioning, machine sensitivity, luciferin delivery technique, 
and measurement acquisition time (O'Neill, Lyons et al. 2010). The impact of 
confounding factors in 2D in vitro systems is relatively limited. BLI signal shows a linear 
relationship with viable cell number with little influence from variations in cell seeding 
density or time in culture (Sun, Lee et al. 2009, Giannoni, Scaglione et al. 2010). In 3D 
cell culture systems, BLI signal is affected by a range of additional variables such as 
luciferin transport kinetics and light scattering properties of the construct (O'Neill, Lyons 
et al. 2010, Liu, Hilderink et al. 2013). BLI measured from cells seeded within constructs 
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of significantly different material properties has been found to differ in magnitude, but to 
be linearly correlated to luciferase content when evaluated in vitro (Logeart-Avramoglou, 
Oudina et al. 2010). 
Given the complexity of the 3D system in vitro, this evaluation becomes even 
more complicated when the 3D construct is implanted. The validity of BLI technique has 
not been rigorously evaluated for these 3D systems in vivo. While many confounding 
factors can be mitigated through implementation of consistent experimental practice, the 
development of tissue ingrowth within and around scaffolds over time is unavoidable and 
fundamental to tissue engineering procedures. Several studies that have demonstrated the 
feasibility of using BLI to track delivered cells for several weeks following implantation, 
have also observed the development of various tissue types (including vascular, fibrotic, 
and mineralized) within constructs over the associated time-course (Olivo, Alblas et al. 
2008, Geuze, Prins et al. 2010, Giannoni, Scaglione et al. 2010, Logeart-Avramoglou, 
Oudina et al. 2010, Rustad, Wong et al. 2012, Bago, Aguilar et al. 2013). Thus, the 
impact of this tissue invasion on the accuracy of BLI measurement remains unclear. 
The work in this aim constitutes an initial examination of longitudinal BLI 
technique applicability for use with a cell-seeded construct of large volume (>200 mm3), 
approaching the scale necessary to evaluate clinical applicability (Muschler, Nakamoto et 
al. 2004). Luciferase-labeled human mesenchymal stem cells (hMSCs) were delivered 
subcutaneously within two hydrogel systems to investigate firstly, the effects of cell dose 
and construct material on cell survival and secondly, the development of contiguous 
tissues, including vascular and fibrotic. Our objectives were to develop a technique 
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capable of tracking hMSCs implanted within large volume constructs and assess the 
potential influence of construct material and tissue ingrowth on in vivo BLI measurement. 
 
3.2 Materials and Methods 
3.2.1 hMSC Culture  
Bone marrow-derived human mesenchymal stem cells (hMSCs) harvested from 
male donors 20-25 years old, with established multipotency, were purchased from the 
Texas A&M University Health Science Center, College of Medicine. Two individual 
donor cell lines were expanded at a starting density of 50 cells/cm2 on petri dishes in 
Minimum Essential Medium alpha (αMEM) containing 16.7% fetal bovine serum (FBS; 
Atlanta Biologicals; Lawrenceville, GA) and 100 units/mL penicillin/100 µg/mL 
streptomycin/2 mM L-glutamine (PSL; Invitrogen; Carlsbad, CA) at 37ºC and 5% CO2. 
For all cell culture conducted in this study, medium was changed twice weekly unless 
otherwise stated. At passage 2, cells from each donor were detached using 0.25% trypsin-
EDTA (Invitrogen), combined in a 1:1 ratio to produce a pooled hMSC population, and 
then plated for lentiviral labeling at a density of 3,500 cells/cm2. 
3.2.2 hMSC Labeling 
Cells were co-transduced using a lentiviral vector containing green fluorescent 
protein (GFP) and firefly luciferase (Luc) downstream of the ubiquitin promoter as 
previously described (Sun, Lee et al. 2009, Sheyn, Kallai et al. 2011). Briefly, hMSCs 
were suspended in polybrene (Sigma; St. Louis, MO) and viral vector at a MOI of 20 and 
incubated in flasks at a density of 10,000 cells/cm2 overnight. Culture medium was 
replaced daily for 3-5 days, during which time the labeling efficiency of GFP/Luc hMSCs 
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was determined using fluorescence microscopy (Axio Observer; Carl Zeiss; Thornwood, 
NY) and flow cytometry (Accuri C6; BD Biosciences; San Jose, CA). Labeled hMSCs 
were replated at 500-700 cells/cm2 and cultured for 5-7 days prior to analysis of 
proliferation, luciferin exposure, or in vivo construct preparation. In situ proliferation of 
labeled and unlabeled hMSCs (n=5) was measured using uptake of bromo-2'-deoxy-
uridine (BrdU) (Roche Applied Science; Indianapolis, IN). Cells, plated at a density of 
8,000 cells/cm2, were incubated with BrdU for 90 minutes following 48 hours of culture. 
Subsequent steps were carried out according to manufacturer’s instructions, using a DAPI 
nuclear counterstain (Invitrogen) prior to image acquisition. ImageJ (U.S. National 
Institutes of Health; Bethesda, MD) was used to quantify BrdU+ and DAPI+ events in 
triplicate for each sample. To investigate potential luciferin toxicity on cell viability, 
hMSCs (n=6) were plated at 2,000 cells/cm2 and exposed to either continual (31.5 
µg/mL) or pulsed (31.5 µg/mL for two 20-minute sessions) beetle luciferin (Fisher 
Scientific; Hampton, NH) or vehicle only. After 48 hours, samples were harvested for 
DNA content using the Quant-iT PicoGreen dsDNA Kit (Molecular Probes; Eugene, 
OR). 
3.2.3 Alginate/Mesh and Agarose/Mesh Construct Preparation 
A dual-syringe protocol, similar to that previously described by Kolambkar et al. 
(Kolambkar, Dupont et al. 2011) for production of acellular constructs, was adapted to 
embed the GFP/Luc hMSCs within hydrogels (final weight percentage 2% w/v). Cells 
were embedded in low molecular weight irradiated RGD-functionalized alginate (FMC 
BioPolymer; Ewing, NJ) (Alsberg, Kong et al. 2003, Silva and Mooney 2007) or 
SeaPlaque Agarose (Lonza; Basel, Switzerland) at densities of 0, 0.25, 0.5, 1.0, and 2.0 
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x106 cells/150 µL of gelled volume (Figure 1A). Following incorporation of hMSCs, 
alginate hydrogels were cross-linked by adding calcium sulfate (Sigma) to a final 
concentration of 8.4 mg/mL. Constructs, prepared by injecting 150 µL of cell-seeded 
hydrogel into an electrospun, polycaprolactone (PCL) nanofiber mesh tube (Kolambkar, 
Dupont et al. 2011), were then incubated in culture medium on custom made vertical 
supports within a 24-well low-attachment plate (Corning, Lowell, MA) for 2-6 hours 
prior to implantation (Figure 1B). To evaluate hMSC viability and distribution following 
inclusion in hydrogels, constructs (n=3) were stained with ethidium homodimer using a 
LIVE/DEAD Kit (Invitrogen) and imaged using an inverted microscope. To confirm 
seeding density, alginate and agarose hydrogels (n=3) ranging 0-1.0 x106 hMSCs/150 µL 
were evaluated for cell viability using the CellTiter-Blue assay (Promega; Fitchburg, 
WI). The viability assay was conducted according to manufacturer’s instructions using a 







Figure 1: Hydrogel/Mesh Construct Preparation A) To produce hMSC-seeded 
hydrogels, components were added to 1-mL Luer-Lok syringes, attached via syringe 
connector, and mixed for 15 seconds. B) Resulting hydrogels were injected through a 20-
gauge into PCL nanofiber mesh tubes (150 µL per construct) and incubated in control 
media prior to implantation. 
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3.2.4 Subcutaneous Implantation in Nude Rats 
All animal procedures were conducted in accordance with the Georgia Institute of 
Technology Institutional Animal Care and Use Committee (IACUC) protocol #A10021. 
Eighteen 11-week-old female, athymic nude rats (Charles River Labs; Wilmington, MA) 
were anesthetized using isoflurane. Two incisions were made slightly lateral to the spine 
of each animal and a custom made tunneling device was used to create four subcutaneous 
pockets. One construct was placed in each pocket. Alginate or agarose constructs 
containing 0, 0.25, 0.5, 1.0, or 2.0 x106 hMSCs (n=4) were implanted in a balanced 
manner, such that every group contained an implant placed at each of the subcutaneous 
pocket locations and samples were randomly distributed across the operated animals. 
Following construct implantation, incisions were closed using suture and wound clips and 
rats were maintained under anesthesia to perform Day 0 BLI. After imaging, a 0.03 
mg/kg subcutaneous dose of buprenorphine was administered to each animal. On Day 7, 
these samples were assessed for cell survival, construct vasculature, and histology. 
3.2.5 In Vivo BLI 
BLI was performed on each animal at Days 0 and 7. Rats were anesthetized using 
isoflurane and 300 µL luciferin (21 mg/mL in saline) was injected subcutaneously at a 
distance of 2-4 mm from the construct site. Using an in vivo imaging system (IVIS) 
Lumina machine (Caliper Life Sciences; Hopkinton, MA), animals were positioned with 
lateral side facing up and scanned at 10, 20, and 30 minutes post luciferin injection (10 
second exposure; 12.5 cm field of view). The animals were then scanned on their other 
side and maintained in the dorsal position when not actively being scanned. BLI images 
were evaluated by demarcation of a 4 cm2 elliptical region of interest (ROI) centered on 
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each construct using Living Image software version 3.2 (Caliper Life Sciences). BLI 
counts were normalized first by exposure time and ROI area and then to the 
corresponding Day 0 value for each sample. BLI signal profile values were calculated by 
normalizing the difference between two same-day BLI measures by the BLI value 
obtained at 30 minutes. 
3.2.6 Construct Vasculature Quantification 
Following Day 7 BLI acquisition, ten rats underwent a vascular perfusion 
protocol modified from Duvall et al. (Duvall, Taylor et al. 2004, Boerckel, Uhrig et al. 
2011). Briefly, after induction of anesthesia, rats were maintained at 4% isoflurane and 
the thoracic cavity opened to insert an 18 gauge catheter (SURFLO Teflon IV catheter; 
Terumuo Medical; Somerset, NJ) through the left ventricle of the heart into the ascending 
aorta. The inferior vena cava was cut and 0.9% saline was perfused through the 
vasculature using a peristaltic pump (Masterflex; Cole Parmer; Vernon Hills, IL) until 
complete clearance was achieved. A solution of 0.9% saline containing 0.4% (w/v) 
papaverin hydrochloride was then perfused followed by 10% neutral buffered formalin 
(NBF) for 5 min. Animals received a final perfusion of 20-25 mL of the radiopaque 
contrast agent Microfil (Flow Tech; Carver, MA) and were left to cure at 4ºC overnight. 
In this way, animals were euthanized by the combined effects of isoflurane overdose and 
exsanguination. Explants were then excised, incubated in NBF for 24 hours, and imaged 
via microcomputed tomography (µCT) scans on a MicroCT42 (Scanco Medical; 
Brüttisellen, Switzerland) at 55kVp, 145µA, and a 12µm voxel size. Acquired slices were 
contoured to define a volume of interest (VOI) of tissue within the construct interior 
alone. To segment perfused vasculature from the surrounding soft tissue within each 
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construct, a range of global thresholds were applied and evaluated by visual inspection to 
determine a minimum threshold value which best reflected the 2D grayscale tomograms. 
This threshold and a low-pass Gaussian filter (sigma=1.2, support=2) were then applied 
to all explants evaluated. 
3.2.7 Histological Analysis 
Perfused samples were prepared for histological analysis following µCT scans. 
Constructs were paraffin embedded and 5µm-thick sections were cut using a microtome 
(Microm; Walldorf, Germany). Masson’s trichrome and immunostaining for von 
Willebrand factor (vWF) were performed and images were collected using an Axio 
Observer fluorescent microscope (Zeiss). vWF staining was conducted using overnight 
incubation with rabbit anti-rat vWF primary (Abcam; Cambridge, MA) at 1:200 dilution, 
followed by an incubation of Alexa Fluor 568 donkey anti-rabbit secondary antibody 
(Invitrogen) and DAPI counterstain. Incubation in serum-free protein block (Dako; 
Carpinteria, CA) preceded application of each antibody. 
3.2.8 Digest of Alginate/Mesh Explants and Flow Cytometry 
In a parallel study to evaluate the applicability of Day 7 BLI measurement, 
alginate constructs containing a range of cell densities up to 1.0 x106 hMSCs were 
implanted using the previously described technique. Following Day 7 BLI, these 
constructs were analyzed using ex vivo flow cytometry. Rats were euthanized by CO2 
asphyxiation and constructs removed by careful dissection. Each explant was cut into ten 
pieces, placed in a digest solution of 1 mg/mL collagenase 1A (≥125 U/mg; Sigma) in 
Hank’s Balanced Salt Solution (HBSS; Invitrogen), and incubated on a rocker plate at 
37ºC for 30-40 minutes. After this time, digest solutions were analyzed by flow 
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cytometry until 20,000 live cell events had been collected or 2 minutes had expired. The 
remaining solution was then diluted in 10 mL of isotonic solution and analyzed using a 
Multisizer 3 Coulter Counter (Beckman Coulter; Brea, CA) which measures cell size and 
number distribution. A Flow Cytometry Size Calibration Kit (Invitrogen) was used to 
equate forward scatter (FSC) values from flow cytometry with diameter data from the 
Multisizer to obtain estimates of the live cell events per construct. 
3.2.9 Data Analysis 
For flow cytometry analysis of labeling efficiency on cell cultures, a GFP+ 
threshold was set using an unlabeled hMSC population with the assumption that 95% of 
the events were sub-threshold. Data were analyzed using one-way and two-way analyses 
of variance (ANOVA) with Tukey post hoc analyses and Minitab software (State 
College, PA,) unless otherwise stated. Linear regressions were conducted using 
GraphPad Prism 5 software (GraphPad Software; La Jolla, CA). For flow cytometry 
analysis of digested explants, the GFP+ event threshold was set at 20-fold higher than the 
mean GFP emission value for each sample to negate interference from surrounding tissue 
debris. A linear regression was performed on the Day 7 BLI vs. GFP+ events data for all 
samples. Correlations between BLI and vascular data were assessed using GraphPad 
software (two-tailed analysis; assumed Gaussian distribution) and data from cell-seeded 
constructs only. After performing a Grubbs’ test on the acquired vascular data for each 
hydrogel type, one sample in the alginate construct data set was found to be a 
mathematical outlier and excluded from the analysis. Data are displayed as mean +/- 
standard error of mean (SEM) with corresponding values of n and statistical significance 




3.3.1 Validation of hMSC Labeling and Construct Embedding 
GFP/Luc-labeled hMSCs retained a fusiform morphology and expressed GFP as 
early 24 hours following lentiviral co-transduction, as indicated by fluorescent 
microscopy (Figure 2A). Flow cytometry determined that the labeling efficiency was 
sufficient for in vivo tracking, with approximately 92% of hMSCs expressing GFP 
(Figure 2B). To investigate any impact of labeling on cell phenotype, proliferation and 
viability assays were conducted in vitro. Labeling did not impact hMSC proliferation and 
frequency of luciferin exposure had no effect on hMSC viability in culture (Figure 2C, 
D). 
In preparation for in vivo delivery, the dual-syringe protocol used to embed 
hMSCs within hydrogel constructs was evaluated for resulting cell viability and seeding 
accuracy. It was determined that sufficient hMSC viability, GFP expression, and spatial 
distribution were achieved for both hydrogel types (Figure 3A). hMSC seeding density 
was validated for both agarose and alginate hydrogels (Figure 3B). Embedded cell dose 
was linearly related to metabolic activity for agarose (r2=0.992) and alginate (r2=0.977) 
gels. Spatial distribution of the embedded hMSCs was also confirmed using confocal 








Figure 2: Characterization of GFP/Luc-Labeled hMSCs A) Labeled hMSCs retained 
a fusiform morphology and expressed GFP (green) as early as 24 hours following 
lentiviral co-transduction (scale bar = 100 µm). B) Flow cytometry analysis of GFP 
expression showed 91.9% cells to be labeled. C) hMSC proliferation was not affected by 
GFP/Luc labeling. D) Frequency of luciferin exposure had no impact on hMSC viability 









Figure 3: Evaluation of Dual-Syringe Hydrogel/Cell Delivery Labeled-hMSCs were 
incorporated into 2% w/v hydrogels using a dual-syringe technique. A) Seeded hMSCs 
remained largely viable (live = GFP (green); dead = ethidium homodimer (red)), retained 
GFP expression, and were well distributed following embedding (scale bar = 500 µm). B) 
Metabolic assays showed strong positive correlation to the seeding density of hMSC-









Figure 4: hMSC Spatial Distribution Following Dual-Syringe Technique Unlabeled 
hMSCs were incorporated into 2% agarose or RGD-alginate (0.25 million cells per 150 
µL hydrogel), stained with calcein and ethidium homodimer, and imaged using confocal 
microscopy. Z-stack images illustrated the viability and spatial distribution of live (green) 





3.3.2 Development and Implementation of BLI Tracking Protocol 
hMSC-seeded constructs ranging in cell dose up to 2.0 x106 were subcutaneously 
implanted and Day 0 BLI was conducted at 10, 20, and 30 minute timepoints following 
injection of luciferin substrate (Figure 5A). Linear regression analysis demonstrated a 
strong relationship between BLI signal and cell number for each hydrogel type 
irrespective of BLI measurement time. The highest correlation coefficients for agarose 
(r2=0.71) and alginate (r2=0.91) constructs were observed using the 30 minute acquisition 
time (Figure 5B, C). Although a similar BLI protocol was effective for both hydrogel 
types, the magnitude of BLI signal differed with hydrogel type such that alginate 
constructs exhibited approximately 2-fold greater counts than agarose constructs at 
comparable hMSC doses.  
To evaluate the effects of hydrogel type and cell dose on hMSC survival, BLI 
data obtained using the 30 minute acquisition protocol on Days 0 and 7 in vivo were 
compared. Although all agarose groups showed a decrease in live cell number over one 
week, the 0.25 x106 cell dose displayed a significantly higher cell survival ratio (67%) 
compared to all other doses (Figure 5D). For the alginate delivery vehicles, only the 
highest two cell doses exhibited a significant decrease in cell number (Figure 5E). By 
Day 7, a larger percentage of hMSCs remained viable for the 0.25 x106 cell dose group 







Figure 5: Development of BLI Protocol and Determination of hMSC Survival 
Agarose and RGD-alginate constructs were used to deliver a range of hMSC cell doses: 0 
- 2.0 x106. Positive correlation between BLI signal and implanted cell number was 
observed at all imaging acquisition time points (10, 20, and 30 minutes) following 
luciferin delivery. A) Representative BLI heat-maps for agarose and alginate constructs 
using the 30-minute BLI protocol are shown. B) For agarose hydrogels, the highest 
correlation coefficient (r2 = 0.706) was observed using the 30-minute BLI protocol. C) 
The best fit (r2 = 0.912) for alginate hydrogels was also achieved using the 30-minute 
BLI protocol. D) By Day 7 post implantation, the number of live cells had decreased in 
all agarose cell groups, with the 0.25 x106 dose exhibiting proportionately the greatest 
cell survival. E) Within the alginate delivery system, the higher cell groups showed 
proportionately smaller live cell numbers after one week. The 0.25 x106 cell dose group 
had improved hMSC survival in comparison to the 2.0 x106 dose. ($ = p < 0.05 as 





3.3.3 Longitudinal Assessment of BLI Protocol 
To investigate the applicability of BLI measurement following implantation in 
vivo, hMSC-seeded alginate constructs were explanted at one week and subjected to ex 
vivo analysis using flow cytometry. While Day 7 BLI counts were significantly correlated 
to GFP+ events under flow (Figure 6A), goodness of fit (r2=0.422) was less than that 
observed on Day 0 (Figure 5C). In addition to examining the BLI signal for each 
construct on Day 7, BLI signal profile (defined as the change in BLI signal over the 30 
minutes following luciferin delivery) was evaluated. The BLI signal profiles for alginate 
constructs on Day 7 suggested a delay in signal rise over the 30 minute imaging span 
compared to Day 0 (Figure 6B). This observation was supported quantitatively by 
evaluating the BLI signal at 10 minutes (BLI10min/BLI30min) for each construct group. This 
value was significantly decreased at Day 7 compared to Day 0 for both agarose and 









Figure 6: Shift in BLI Profile after 1 Week In Vivo A) At Day 7, construct BLI was 
positively correlated to GFP+ events (r2 = 0.422). B) BLI signal exhibited a delayed 
increase to 30-minute value after one week in vivo (solid line = Day 0 average; dashed 
line = Day 7 average). Day 0 and Day 7 cell dose averages represented by solid and 
outlined symbols, respectively. C) For agarose constructs, the increase in BLI signal 
following luciferin injection was attenuated on Day 7 compared to Day 0. D) Alginate 






Tissue development within and exterior to the constructs on Day 7 was assessed 
using Masson’s trichrome staining for fibrotic tissue. Tissue growth was localized 
predominantly to the construct exterior (Figure 7A). Irrespective of hydrogel type and 
cell dose, the construct mesh was lined with a layer of cells and fibrotic tissue. Construct 
interiors were composed of hydrogel islands containing vacant and cell-occupied pockets 
(Figure 7B). Qualitatively, pocket density appeared to be dependent on the initial cell 
dose, but independent of hydrogel type. The extent of tissue infiltration through 
macroscopic mesh pores and tube ends of each construct was variable and unrelated to 
hydrogel type, cell dose, or Day 7 BLI signal attenuation (Figure 7C, D). Although all 
samples contained a fibrous capsule, capsule thickness and vascularization were 
inconsistent and did not appear related to experimental group, interior construct 









Figure 7: Construct Encapsulation and Tissue Ingrowth at 1 Week In Vivo A) 
Construct interiors were predominantly comprised of hydrogel islands (H) and the 
nanofiber mesh (M) exterior was lined with cells (red), fibrous capsule (blue), and 
regions of vascularized tissue (perfusion agent = black, indicated by yellow arrows; scale 
bar = 100 µm). B) Hydrogel islands within the construct interior contained vacant and 
cell-occupied pockets. Alginate constructs of acellular (above) and 2 x106 cell dose 
(below) are shown (scale bar = 500 µm). C) Tissue ingrowth through macroscopic pores 
(P; labeled in upper image only) in the construct mesh was variable (scale bar = 500 µm). 
D) Fibrous capsule extended along the mesh exterior and across the tube end. Construct 






3.3.4 Construct Vasculature 
µCT reconstruction of the explant vasculature illustrated the presence of blood 
vessels surrounding the nanofiber mesh exterior as well as infiltrating the construct 
through 1mm-diameter macropores in the tube (Figure 8A). Quantification of vessel 
volume within the construct interior determined that all groups contained vasculature and 
there was no difference between cell dose groups for either hydrogel type (Figure 8B, C). 
Histological analysis was used to corroborate vascular perfusion data (Figure 8D). Both 
agarose and alginate groups showed pockets of perfusion contrast agent contained within 
immature vasculature localized near the construct periphery. Specificity of the perfusion 
technique was supported by co-localization of the contrast agent and vWF 
immunostaining. 
The association between development of vasculature and live cell number (BLI 
signal) on Day 7 was examined. For agarose constructs, there was no correlation between 
vascular volume and either BLI signal (30-minute measurement) or BLI signal profile 
(Figure 9A, B). Alginate constructs showed no correlation between live cell number (BLI 
signal) and vascular volume on Day 7 (Figure 9C). However, alginate construct 
vasculature was significantly correlated to BLI signal profile (Figure 9D). Higher 
vascular volumes were associated with a smaller rise in BLI signal during the first 10 







Figure 8: Construct Vascularization at 1 Week Post Implantation In Vivo A) Blood 
vessels were present along the construct exterior (orientation as indicated by illustration) 
as well as infiltrating macropores of the nanofiber mesh tube (axial view; dashed line 
signifies location of vascular contouring). B) Agarose construct vascular volume was 
independent of delivered hMSC dose. C) hMSC dose did not impact vasculature formed 
within alginate constructs. D) Vasculature (indicated by yellow arrows) within agarose 
and alginate constructs was confirmed histologically by brightfield microscopy 
(perfusion agent = black) and vWF immunostaining (endothelium = red, cell nuclei = 












Figure 9: Construct Vascularization and BLI Signal Profile with Hydrogel Type A) 
30-minute BLI signal and vasculature for hMSC-seeded agarose constructs were not 
correlated. B) Construct vasculature did not impact the BLI signal profile for agarose 
delivery vehicles on Day 7. C) 30-minute BLI signal and vasculature for alginate 
constructs were not correlated. D) Vascular volume perturbed the BLI signal profile for 
alginate constructs on Day 7. Increased vasculature was negatively correlated with an 
increase in BLI signal over the initial 10 minutes following luciferin injection and 






BLI has emerged an invaluable optical imaging technique for the development of 
cancer therapies and cell-based regenerative medicine strategies within experimental 
models (O'Neill, Lyons et al. 2010, de Almeida, van Rappard et al. 2011). In preparation 
to implement this monitoring tool in subsequent dissertation aims, we first developed and 
characterized a BLI protocol compatible with our large, multi-component delivery 
platform. Additionally, this effort investigated the effect of hydrogel type on BLI 
measurement and delivered hMSC viability. 
Following subcutaneous implantation of agarose/mesh and alginate/mesh 
constructs, we found a strong correlation between BLI signal and viable cell number 
within each hydrogel type at Day 0. The implementation of a 30-minute window between 
luciferin injection and BLI acquisition provided a good representation of live cell number 
contained within these systems while operating within the constraints of an in vivo model. 
Although both hydrogel types showed a linear correlation between BLI signal and live 
cell number using the 30-minute imaging protocol, there was a difference in the 
magnitude of BLI signal measured between the agarose and alginate constructs. Previous 
work has noted a difference in BLI signal magnitude for materials of significantly distinct 
opacity and physiochemical properties (Logeart-Avramoglou, Oudina et al. 2010). 
However, the agarose and alginate constructs examined in this study each consist of 
translucent hydrogels reconstituted at similar density. Within these materials, diffusive 
transport is shown to be limited for molecules greater than 6.5-70 kDa, a size roughly 
200-fold larger than that of luciferin (Tanaka, Matsumura et al. 1984, Pluen, Netti et al. 
1999, Drury and Mooney 2003). Therefore, differences in luciferin transport kinetics are 
unlikely to account for the material-dependent magnitude of BLI signal. The observed 
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phenomenon could be due to a difference in construct light scattering properties resulting 
from dissimilar hydrogel rearrangement behavior. Following syringe-injected construct 
preparation, the ionically cross-linked alginate is capable of reforming under 
physiological conditions whereas agarose hydrogel would require a temperature increase 
in order to reassemble (Pluen, Netti et al. 1999, Lee and Mooney 2012). 
Irrespective of hydrogel type, the lower cell doses were found to survive one 
week in vivo proportionally better than the high cell doses. Although the presence of a 
necrotic core is not seen in vitro, it is possible that cells compete for nutrients and only a 
fraction of the implanted cells could be supported in vivo. This is suggested by the fact 
that, in contrast to the proportional viability just discussed, there were no differences in 
absolute live cell number between groups on Day 7. This might indicate the attainment of 
an equilibrium live cell number that can be initially supported or sustained in the absence 
of an integrated vasculature. The alginate constructs supported improved hMSC viability 
in comparison to the agarose vehicles. This may be due to functionalization of the 
alginate hydrogel with the RGD peptide in order to facilitate cell attachment and 
manipulation (Lee and Mooney 2012). In the absence of RGD modification, agarose and 
alginate hydrogels lack adhesive sequences, resulting in abnormal morphology and 
reduced viability of encapsulated cells (Awad, Wickham et al. 2004).  
Despite its employment for tracking viability and location of injected cells in vivo, 
BLI has yet to be validated for large 3D cellular constructs. Variations in tissue ingrowth 
over time following implantation lead to development of an inherently noisy system for 
optical imaging analysis (Muschler, Nakamoto et al. 2004). Even in vitro, transport 
properties of cell-seeded agarose and alginate hydrogels change over time in culture, 
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presumably due to cell-mediated matrix synthesis (Leddy, Awad et al. 2004). Previous 
work has corroborated in vivo BLI measurement to ex vivo construct analysis of 
luciferase content or histological staining (Jenkins, Oei et al. 2003, Olivo, Alblas et al. 
2008, Logeart-Avramoglou, Oudina et al. 2010, Becquart, Cambon-Binder et al. 2012). 
In this report, we evaluated BLI measurement of large constructs subsequent to tissue 
ingrowth in vivo by directly quantifying labeled cell number on a whole construct basis. 
BLI signal correlated linearly to GFP+ flow cytometry events with a coefficient lower 
than that observed on Day 0. This reduction in correlation is suggestive of confounding 
variables present within the system on Day 7.  
An examination of the factors which could affect the BLI signal on Day 7 reveals 
the dependency of BLI signal on oxygen and ATP levels within the tissue engineered 
constructs (O'Neill, Lyons et al. 2010). This is generally viewed as a positive feature, as it 
constrains measurement to the presence of live cells. However, in exceptionally hypoxic 
environments, such as those simulating a tumor necrotic core, oxygen can become rate 
limiting within the bioluminescent system (Moriyama, Niedre et al. 2008). Aside from 
the luciferase enzyme, photon release is highly dependent on the availability of luciferin 
substrate. Luciferin is a small molecule that readily diffuses through tissue (Honigman, 
Zeira et al. 2001). However, endogenous cell populations may deplete luciferin en route 
to the labeled cells of interest through uptake of substrate across the cell membrane 
(Berger, Paulmurugan et al. 2008). Adding to the complexity of luciferin availability, 
vascular networks have the potential to impact substrate delivery by providing a means of 
convective transport.  
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 For both agarose and alginate constructs, increase of BLI signal over the 30-
minute imaging window was attenuated on Day 7 in comparison to Day 0. To investigate 
whether the modified BLI profile might be attributed to hindered luciferin transport 
kinetics, tissue within and proximal to the explant on Day 7 was examined by histology. 
Neither fibrous capsule thickness nor degree of the peripheral vascular network exhibited 
a relationship to hydrogel type, initial cell dose, or Day 7 BLI profile.  However, the 
presence of a fibrous capsule across all experimental groups may be responsible for the 
attenuated BLI profile observed on Day 7, as a logical consequence of such tissue 
development would be restricted luciferin availability. 
Although MSC delivery has been shown to promote angiogenic and vasculogenic 
processes, this effect was not significant in the current study, perhaps due to particulars of 
the vehicle or timescale examined (Au, Tam et al. 2008, Egana, Danner et al. 2009, 
Jackson, Nesti et al. 2012). Vasculature did weakly correlate to BLI signal behavior in 
the alginate constructs over the 30-minute imaging window, suggesting an impact of 
vascular volume on luciferin availability within the construct. Interestingly, greater 
vasculature correlated to a delayed rise in BLI signal following luciferin delivery 
initially, but then accelerated BLI signal increase between 10 and 30 minutes. No 
correlations were observed in the agarose constructs. These results provide further insight 
on the temporal and matrix dependent effects of vasculature on BLI measurements 
(Levenberg, Rouwkema et al. 2005).  
 In support of our Aim I hypothesis, these results validate that BLI can be 
implemented to longitudinally track hMSC number within our large, multi-component 
delivery system. However, this work draws attention to the impact of hydrogel carrier 
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type as well as tissue and vascular ingrowth on longitudinal BLI measurement. Such 
observations motivate that validation of BLI protocol and investigation of potentially 
confounding variables be conducted on a system-by-system basis in order to draw 
representative conclusions. Subsequent application of BLI tracking within this 
dissertation considered the limitations of this analytical technique in evaluating the 
potential impact of platelet lysate utilization and cell aggregation on implanted MSC 
survival. Furthermore, results from this study encouraged continued testing of the 
alginate carrier platform on the basis of its improved support of hMSC viability 





CHAPTER 4  EVALUATION OF HUMAN PLATELET LYSATE 
FOR MESENCHYMAL STEM CELL DELIVERY 
 
4.1 Introduction 
 Human platelet lysate (hPL), a solution produced from platelet-rich plasma (PRP), 
is enriched in growth factors including platelet-derived growth factor (PDGF), vascular 
endothelial growth factor (VEGF), latent transforming growth factor beta (TGF-β), 
insulin-like growth factor (IGF), basic fibroblast growth factor (bFGF), and epidermal 
growth factor (EGF) (Reed, Fitzgerald et al. 2000, Rendu and Brohard-Bohn 2001, King 
and Reed 2002, Maguire and Fitzgerald 2003, Lohmann, Walenda et al. 2012). hPL has 
been explored as a substitute to fetal bovine serum (FBS) for cell culture and found to 
have advantages exceeding that of eliminating xenogeneic concerns. Exposure of human 
mesenchymal stem cells (hMSCs) to hPL in vitro has positive effects including increased 
proliferation, decreased doubling time (DT), maintained immunophenotype, and delayed 
senescence (Doucet, Ernou et al. 2005, Muller, Kordowich et al. 2006, Reinisch, 
Bartmann et al. 2007, Schallmoser, Bartmann et al. 2007, Carrancio, Lopez-Holgado et 
al. 2008, Avanzini, Bernardo et al. 2009, Azouna, Berraeis et al. 2011, Flemming, 
Schallmoser et al. 2011, Griffiths, Baraniak et al. 2013, Rubio-Azpeitia and Andia 2014). 
 Although hPL has predominantly been explored in liquid form, its fibrinogen 
content enables it to produce a hydrogel as well (Harrison and Cramer 1993, Walenda, 
Hemeda et al. 2012). The initial objectives of this thesis aim were to examine whether 
hPL could be implemented as either a pre-treatment or co-delivery strategy to augment 
the (i) survival and (ii) facilitated bone regeneration of hMSCs delivered within alginate 
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matrices. However, in pursuing these studies, concerns arose as to whether the utility of 
hPL could be accurately informed using rodent pre-clinical testing models. Thus, 
immunocompromised (Nude rat) and syngeneic (Lewis rat) animal models were studied 
for issues of xenogenicity and species variability. 
 Immunocompromised animal models, such as the athymic Rowett nude (rnu) rat, 
enable pre-clinical testing of human components (e.g. proteins, cells, and tissues) due to 
deficient T-cell-mediated immune response (Festing, May et al. 1978, Berridge, O'Kech 
et al. 1979, Rolstad 2001). However, while Nude rats are without T cell function, the 
activities of other lymphocyte subtypes, including B cells and natural killer cells, remain 
conserved (de Jong, Steerenberg et al. 1980, Vos, Kreeftenberg et al. 1980). Furthermore, 
in addition to immune defenses imparted by the host, mechanisms retained in the 
delivered human therapeutic must be considered as well. A range of anti-animal 
antibodies is naturally occurring in human circulation and thereby present in collected 
PRP (Kricka 1999, Cramer 2000, Dhurat and Sukesh 2014). Existence of xenoantibodies 
in combination with complement proteins, the concentrations of which are amplified 
upon lysis of platelet α-granules during hPL production, allow for the possibility of 
classical or alternative complement system activation resulting in membrane attack 
complex (MAC)-mediated host cell death (Romanella, Aminian et al. 1997, Blair and 
Flaumenhaft 2009, Rubio-Azpeitia and Andia 2014, Morgan 2015). Apart from immunity 
related challenges, species mismatch between the delivered components (hMSCs and 
hPL) and endogenous cell populations present within an immunocompromised model 
system could potentially limit observed therapeutic efficacy (Zara, Siu et al. 2011). 
 Limitations of an autologous or syngeneic rodent model, such as the inbred Lewis 
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rat, include species-dependent properties of the therapeutic components being 
scrutinized. Interspecies variability of bone tissue characteristics includes biochemical 
composition, osteoblast phenotype, and osteoinduction behavior (Aerssens, Dequeker et 
al. 1994, Aspenberg and Turek 1996, Yang, Yuan et al. 1996, Torricelli, Fini et al. 2003). 
Of particular interest for cell-based bone regeneration strategies is the divergent behavior 
of human vs. rat MSCs, comprised of distinct immunosuppressive, cell signaling, and 
osteogenic differentiation characteristics (Chaudhary and Avioli 1997, Ren, Su et al. 
2009, Huang, Cai et al. 2013). Variation in platelet properties as a function of animal 
species has been previously explored, uncovering both significant similarities and 
differences in platelet proteome depending on the study and species examined (van den 
Dolder, Mooren et al. 2006, Yu, Leng et al. 2010). While delivery of platelet-derived 
plasma (PRP) has promoted bone repair within several species-matched models, 
including rat and rabbit, the effect of platelet-derived factors on cell-based bone 
regeneration is left minimally interrogated (Rai, Oest et al. 2007, Zhang, Huang et al. 
2013). Even in culture, the impact of exposing rMSCs to rPL-supplemented media is 
largely unproven in comparison to the well-established hMSC/hPL relationship. Some 
studies have found the exposure of rMSCs to rat platelet-derived factors to further 
proliferative or osteogenic capacity, yet these findings remain preliminary due to a 
scarcity of corroborating investigations (van den Dolder, Mooren et al. 2006, Huang and 
Wang 2012).  
 The following research examined the utility of hPL as a pre-treatment or co-
delivery strategy to augment hMSC survival and construct vasculature upon implantation 
within an immunocompromised rodent model. Subsequently, the potential limitations of 
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using rodent pre-clinical testbeds for the evaluation of hPL were investigated via in vitro 
experimentation. 
 
4.2 Materials and Methods 
4.2.1 MSC Culture 
 Bone marrow-derived hMSCs were purchased from the Texas A&M University 
Health Science Center and cultured as previously described (Allen, Gazit et al. 2014). 
Briefly, two donor cell lines were expanded in Minimum Essential Medium alpha 
(αMEM) containing 16% v/v fetal bovine serum (FBS; Atlanta Biologicals; 
Lawrenceville, GA) and 100 units/mL penicillin/100 µg/mL streptomycin/2 mM L-
glutamine (PSL; Invitrogen; Carlsbad, CA) at 37ºC and 5% CO2. At passage 2, cells were 
detached using 0.25% trypsin-EDTA (Invitrogen) and combined 1:1 to form a pooled 
hMSC population. Lewis rMSCs, characterized for multipotency, were purchased 
(Sciencell Research Laboratories; Carlsbad, CA) and expanded until passage 2 in similar 
culture conditions.  
4.2.2 Platelet Lysate Preparation 
Recently expired human platelet-rich plasma (PRP) from seven donors was 
acquired from the American Red Cross, pooled, and stored at -20°C (Griffiths, Baraniak 
et al. 2013). Rat PRP was prepared from the whole blood of twelve Lewis rats and 
pooled. In a terminal procedure approved by the Georgia Institute of Technology 
Institutional Animal Care and Use Committee (IACUC) protocol #A10021, blood was 
drawn from anesthetized rats via cardiac stick and transferred to vacutainers containing 
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acid citrate dextrose (BD Worldwide; Franklin Lakes, NJ). Collected blood underwent 
sequential rounds of centrifugation (10 min @ 1,200 RPM, 5 min @ 1,500 RPM, and 5 
min @ 1,500 RPM) using an IEC Centra CL2 (Thermo Scientific; Waltham, MA) with 
the non-erythrocyte volume collected subsequent to each step. Collected product was 
centrifuged (10 min @ 3,500 RPM), concentrated through partial supernatant removal to 
achieve a platelet concentration matching that of the human PRP (1-1.5 x106 
platelets/µL), and stored at -20°C. To generate human and rat platelet lysate (PL), PRP 
was thawed, re-frozen, and thawed a second time. PDGF-AB content (n=3) for each PL 
product was measured via species-specific ELISA assay (R&D Systems; Minneapolis, 
MN). To produce hPL supplemented media, hPL was filtered through a 0.8/0.2 µm 
membrane (Pall Corporation; Port Washington, NY) and added to αMEM containing PSL 
and 2 units/mL heparin (Sagent Pharmaceuticals; Schaumburg, IL). To prepare heat-
inactivated hPL (hPL-HI) media, hPL was heated to 56°C for 30 minutes prior to 
filtration and use. When processed identically to hPL, rPL media was observed to form a 
hydrogel in culture. Thus, rPL supplemented media was prepared using an increased 
heparin concentration (5 units/mL), but otherwise comparably. 
4.2.3 2D In Vitro Analysis 
To investigate the effect of hPL culture on hMSC expansion, passage 3 cells 
(n=9) were expanded over 8 days in FBS (16%) or hPL (5%) supplemented media and 
cell DT was calculated. To determine whether hPL culture had prolonged impact, 
expanded hMSCs were transitioned to serum starvation media containing 1% w/v bovine 
serum albumin (BSA) and cultured under normoxic (17% O2) or hypoxic (5% O2) 
conditions (n=11-12). Change in DNA content through 1 and 3 days was quantified via 
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the Quant-iT PicoGreen dsDNA Kit (Molecular Probes; Eugene, OR). To explore the 
impact of PL culture on MSC expansion over multiple passages, hMSCs (n=3-6) plated 
at 250 cells/cm2 were cultured in FBS (16%) or hPL (5% or 10%) supplemented media 
over 4 days, at which point cells were enumerated. This was repeated twice more, such 
that cell DT was calculated for passages 2-4. rMSCs (n=5-6) cultured in FBS (16%) or 
rPL (5% or 10%) supplemented media were similarly analyzed. To evaluate acute 
response to hPL culture, hMSCs or rMSCs at passage 3 were plated at 5,000 cells/cm2 in 
FBS (16%) media. Following a 48-hr adhesion period, media was switched to FBS 
(16%), no serum (NS), hPL (10%), or hPL-HI (10%) supplemented. Cells were stained 
with calcein and ethidium homodimer at 24 hrs using a LIVE/DEAD Kit (Invitrogen) and 
imaged by inverted microscope (Axio Observer; Carl Zeiss; Thornwood, NY). At 24 hrs, 
C5b-9 supernatant concentration (n=4) and DNA content (n=11-12) were quantified. 
C5b-9 was measured via a MicroVue SC5b-9 Plus assay (Quidel; San Diego, CA) and 
compared alongside negative (acellular) and positive (containing 10% v/v heat-
aggregated immunoglobulin G (HAGG; Quidel) controls. Samples harvested at 0 hrs 
were used to calculate percent change in DNA.  
4.2.4 Alginate Construct Preparation 
 Prior to alginate embedding, hMSCs were lentivirally co-transduced with a vector 
containing ubiquitin promoter-driven expression of green fluorescent protein (GFP) and 
firefly luciferase (Luc) as previously described (Sun, Lee et al. 2009, Sheyn, Kallai et al. 
2011). Using a dual-syringe mixing technique, GFP/Luc hMSCs were incorporated into 
RGD-functionalized alginate (FMC BioPolymer; Ewing, NJ) at a density of 0.5 x106 
cells/150 µL with 0 or 20% v/v hPL. hMSC-seeded hydrogels (2% w/v) were then cross-
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linked via calcium sulfate (8.4 mg/mL; Sigma-Aldrich; St. Louis, MO) and constructs 
were prepared by injecting 150 µL of resultant hydrogel into an electrospun, 
polycaprolactone (PCL) mesh tube. 
4.2.5 3D In Vitro Analysis 
 For the investigation of hPL pre-treatment, hMSC-seeded constructs were 
prepared using GFP/Luc hMSCs expanded in either FBS (16%) or hPL (5%) media. In 
the pre-cultured group, alginate/mesh constructs were assembled 3 days prior to 
implantation and cultured on vertical supports in media matching that of the expansion 
conditions. In the case of direct syringe injection, hydrogels were prepared the morning 
of surgery and constructs were assembled in the surgical suite immediately prior to 
implantation. hMSC viability (n=3) and DNA content (n=4-6) within these treatment 
groups at the time of implantation was evaluated using the LIVE/DEAD (Invitrogen) and 
PicoGreen (Molecular Probes) kits. 
 For investigation of hPL co-delivery, hMSC-seeded constructs with 0 or 20% hPL 
(n=8) were cultured on custom made vertical supports within 24-well low-attachment 
plates over 1 week. Longitudinal bioluminescent imaging (BLI) was performed on Days 
0, 1, 3, and 7. At each timepoint, beetle luciferin (Fisher Scientific; Hampton, NH) was 
added to the culture media (0.21 mg/mL) and incubated 20 minutes prior to image 
acquisition (5 second exposure; 12.5 cm field of view) using an IVIS Lumina machine 
(Caliper Life Sciences; Hopkinton, MA). BLI images were evaluated within the Living 
Image software version 3.2 (Caliper Life Sciences) using a circular region of interest 
(ROI) centered over each well. Total BLI counts were divided by exposure time and ROI 
area (Absolute BLI), then normalized to the corresponding Day 0 value for each sample 
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(Normalized BLI). Culture media (2 mL/well) was replaced following each timepoint. In 
a parallel study, constructs (n=2) were stained at 48 hrs using a LIVE/DEAD kit and 
imaged (Zeiss) to observe cell morphology. Evaluation of hPL release was performed on 
hMSC-seeded and acellular constructs with 0 or 20% hPL (n=4) cultured over 1 week 
with media collected at 4, 12, 24, 72, and 168 hrs and analyzed via hPDGF-AB ELISA 
assay. 
4.2.6 Surgical Procedures 
 Surgical implantation was conducted in accordance with the Georgia Institute of 
Technology IACUC protocol #A10021 as described previously (Allen, Gazit et al. 2014). 
Ten 11-week-old female, athymic nude rats (Charles River Labs; Wilmington, MA) were 
anesthetized using isoflurane. Two dorsal incisions were made to prepare four 
subcutaneous pockets per animal. In the pre-treatment study, hMSCs expanded in FBS 
(16%) or hPL (5%) media were alginate-embedded and either assembled as constructs 3 
days prior to surgery (to allow pre-culture in media matching that of the expansion 
conditions) or assembled as constructs within the surgical suite following syringe 
crosslinking 4-7 hrs prior (n=6; Figure 10A). In the co-delivery study, all hMSC-seeded 
or acellular constructs with 0 or 20% hPL were assembled within the surgical suite 
(n=10; Figure 10B). In all studies, an alginate/mech constructs was delivered to each 
pocket and incisions were closed using suture and wound clips. A 0.03 mg/kg 






Figure 10: hPL Pre-Treatment and Co-Delivery Experimental Designs A) To 
examine hPL as a pre-treatment strategy, labeled hMSCs were expanded in FBS or hPL 
media, assembled into alginate/mesh constructs and either pre-cultured over 3 days or 
immediately implanted. B) To investigate the effect of co-delivered hPL, all hMSCs were 
expanded in FBS media, assembled into alginate/mesh constructs with or without 20% 
v/v/ hPL, and immediately delivered in vivo. 
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4.2.7 In Vivo and Explant Analyses 
 Longitudinal BLI was performed on Days 0 and 7 (pre-treatment study) or Days 
0, 1, 7, and 14 (co-delivery study) using a previously established protocol (Allen, Gazit et 
al. 2014). Rats were anesthetized and 300 µL luciferin (21 mg/mL in saline) was injected 
subcutaneously at a distance of 2-4 mm from each construct site. The animals were 
scanned on either side 30 minutes post luciferin injection (10 second exposure; 12.5 cm 
field of view). BLI images were evaluated by demarcation of a 4 cm2 elliptical ROI and 
calculations were carried out as described in sub-section 4.2.5. Following Day 14 BLI 
acquisition, rats underwent vascular perfusion using an 18 gauge catheter (SURFLO 
Teflon IV catheter; Terumuo Medical; Somerset, NJ) inserted into the ascending aorta 
and peristaltic pump (Masterflex; Cole Parmer; Vernon Hills, IL). Saline (0.9% w/v), 
papaverin hydrochloride (0.4% w/v in saline), neutral buffered formalin (10% v/v), and 
the radiopaque contrast agent Microfil (Flow Tech; Carver, MA) were perfused in order. 
Explants were excised and imaged via microcomputed tomography (µCT) scans on a 
MicroCT42 (Scanco Medical; Brüttisellen, Switzerland) at 55kVp, 145µA, and a 12µm 
voxel size. Acquired slices were contoured and segmented using a low-pass Gaussian 
filter (sigma=1.2, support=2) to evaluate vascular volume within the construct interior 
alone. To reduce variability associated with the perfusion procedure, construct vascular 
volume was normalized by that of the intra-animal “acellular + 0% hPL” group (n=8). 
Following µCT scans, explants were paraffin embedded and histologically sectioned via 
microtome (Microm; Walldorf, Germany). 5µm-thick sections were stained with 
hematoxylin and eosin (H&E) or Masson’s trichrome and imaged (Zeiss). 
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4.2.8 Statistical Analysis 
Values are displayed as mean +/- standard error of mean (SEM) with 
corresponding values of n and statistical significance defined by p<0.05. Data were 
analyzed using two-way analyses of variance (ANOVA) with Tukey post hoc 
comparisons within the Minitab software (State College, PA). For C5b-9 evaluation, 
statistical analysis excluded acellular control groups. 
 
4.3 Results 
4.3.1 Implantation of hMSCs Receiving hPL Pre-Treatment 
 In preparation for in vivo delivery, the effect of hPL (5%) culture on hMSC 
expansion was compared to traditional FBS (16%) supplemented media. hPL culture was 
found to decrease cell doubling time (Figure 11A). Furthermore, upon removal of hMSCs 
from hPL media, the benefits of initial culture showed long-lasting effects. Culture 
conditions produced comparable hMSC expansion through Day 1, as measured via DNA 
content (Figure 11B). However, beneficial effects of preceding hPL culture (p=0.001) 





Figure 11: Effects of hPL Culture on hMSC Expansion A) Expansion in hPL (5%) 
media led to a decrease in cell DT compared to FBS (16%) culture. B) Following 
removal of hMSCs from expansion media stimulus and culture under normoxic or 
hypoxic conditions, no differences in continued expansion were observed through Day 1. 
C) However, by Day 3, improved hMSC expansion resulting from previous hPL culture 
(p=0.001) or subsequent hypoxic conditions (p<0.001) were demonstrated. 
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 Given the promising consequence of hPL pre-treatment on hMSCs in vitro, this 
strategy was further challenged using a subcutaneous implant model. GFP/Luc hMSCs 
were expanded in either FBS or hPL media and then either delivered via immediate 
syringe injection (SI) or construct pre-culture (PC) strategy. Hydrogels delivered in the 
syringe injectable treatment were prepared the morning of surgery and assembled into 
alginate/mesh constructs within the surgical suite immediately prior to implantation. Pre-
cultured alginate/mesh constructs were assembled 3 days before surgery and cultured 
within media matching that of the hMSC expansion conditions. Analysis of hMSC-
seeded treatments at the time of implantation revealed a qualitatively reduced fraction of 
live cells (Figure 12A) and decreased DNA content (Figure 12B) contained within each 
PC group (PC, FBS; PC, PL). 
 In vivo BLI performed immediately following implantation determined that 
significantly fewer hMSCs were delivered within the hPL-expanded, pre-cultured (PC, 
PL) treatment group (Figure 13A). By Day 7, viable cell number within the hPL-
expanded, syringe injected (SI, FBS) and FBS-expanded, pre-cultured (PC, FBS) groups 
decreased from their corresponding Day 0 values. Examining the surviving fraction of 
delivered hMSCs through Day 7, only the FBS-expanded, syringe injected (SI, FBS) 
treatment exhibited no reduction in viable cell number, maintaining hMSC viability better 
than all other delivery strategies (Figure 13B). Despite these differences observed in 







Figure 12: hMSC Viability within hPL Pre-Treatment Groups on Day 0 A) 
Embedded hMSCs (live = GFP (green); dead = ethidium homodimer (red)) displayed 
qualitatively reduced viability in the pre-cultured (PC) alginate/mesh constructs (scale bar 
= 150 µm). B)  Measures of DNA content at the time of implantation were consistant 
microscopy observations, exhibiting decreased DNA in response to construct pre-culture 







Figure 13: hMSC Survival and Construct Vasculature through Day 7 In Vivo A) 
Fewer viable hMSCs were delivered within the hPL-expanded, pre-cultured group (PC, 
PL) on Day 0. B) Delivery of FBS-expanded hMSCs within immediately implanted 
alginate/mesh constructs (SI, FBS) exhibited no decrease in hMSC surviving fraction in 
vivo, outperforming all other treatments strategies by Day 7. C) Pre-treatment strategy 
had no effect on construct vascular volume. (* = p < 0.05 within same timepoint vs. all 
other treatments; $ = p < 0.05 within same treatment vs. Day 0) 
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4.3.2 Addition of hPL to Hydrogels In Vitro 
 Having evaluated the effects of hPL pre-treatment, the potential utility of hPL co-
delivery was explored. hPL (20% v/v) was incorporated into RGD-alginate hydrogels 
using a dual-syringe protocol. Resultant hydrogel was injected into PCL mesh tubes to 
form constructs and cultured over 7 days. Following an initial 48 hrs of culture, alginate-
embedded hMSCs displayed a largely rounded morphology irrespective of whether hPL 
had been added to the hydrogel (Figure 14A). Persistence of incorporated hPL within the 
constructs was monitored by measurement of hPDGF-AB released into the surrounding 
media (Figure 14B). hPDGF-AB released by hPL-containing groups over one week was 
higher for the acellular constructs (p<0.001). Both acellular and hMSC-seeded constructs 
exhibited a burst release of growth factor, with roughly 70% and 95%, respectively, of 
measured hPDGF-AB release occurring during the first 12 hrs in vitro.  
 Addition of 20% hPL to hMSC-seeded constructs promoted an overall increase 
(p<0.001) in live cell number in vitro, as evaluated via absolute (Figure 14C) and 
normalized (Figure 14D) longitudinal BLI. Comparing within timepoints, signal for the 
hPL-containing hydrogels was significantly greater on Day 1, displaying an effect size of 
32% (absolute BLI) or 66% (normalized BLI), depending on the BLI metric. Within 









Figure 14: Addition of hPL to Hydrogels In Vitro A) Embedded hMSCs (live = GFP 
(green); dead = ethidium homodimer (red)) display similar rounded morphology at 48 hrs 
in culture irrespective of hPL addition (scale bar = 100 µm). B) The majority of hPDGF-
AB release from hPL-containing constructs occurred by 12 hrs in vitro, with cumulative 
release over one week being greater for acellular constructs compared to hMSC-seeded. 
C) hPL addition enhanced hMSC live cell number in vitro (p<0.001), as evaluated via 
absolute BLI counts. D) hPL addition enhanced hMSC live cell number in vitro 
(p<0.001), as evaluated via normalized BLI counts. (* = p < 0.05 as indicated; # = p < 
0.05 within same treatment vs. all other days) 
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4.3.3 Implantation of hPL Containing Constructs 
 hMSC-seeded and acellular constructs with or without incorporated hPL were 
implanted subcutaneously in Nude rats and monitored using BLI over 14 days. hPL 
incorporation was observed to have no impact on delivered cell number, as evaluated via 
absolute (Figure 15A) and normalized (Figure 15B) bioluminescent counts. Both 
treatment groups displayed 46-47% and 2% hMSC survival rates through Days 1 and 14, 
respectively. 
 To quantify the impact of hPL and hMSC delivery on construct vascularization, 
rats underwent vascular perfusion on Day 14 and explant vasculature was analyzed using 
µCT. Neither hPL incorporation (p=0.354) nor hMSC delivery (p=0.199) had a 
significant impact on construct vessel volume (Figure 15C). However, representative 
µCT reconstructions indicate that the distribution of vessels throughout the construct may 
have been altered as a function of treatment, with hPL-containing constructs exhibiting 








Figure 15: In Vivo Bioluminescent Imaging (BLI) and Construct Vasculature 
hMSC-seeded and acellular constructs with or without hPL were implanted 
subcutaneously in Nude rats and explanted on Day 14 following vascular perfusion. A) 
hPL co-delivery had no effect on hMSC live cell number in vivo (p=0.084), as evaluated 
via absolute BLI counts. B) Normalized BLI revealed no impact of hPL addition on 
hMSC survival in vivo (p=0.719), with <50% and 2% of cells remaining viable in either 
group on Days 1 and 14, respectively. C) Neither hPL addition (p=0.354) nor hMSC 
delivery (p=0.199) affected construct vascular volume. D) Representative vascular 
reconstructions illustrate that the spatial distribution of vessels may be altered as a 
function of treatment. (# = p < 0.05 within same treatment vs. all other days; * = p < 0.05 





 Tissue development and morphology at the construct interior were examined 
using H&E staining. Compared to all other treatments, acellular constructs lacking co-
delivered hPL exhibited qualitatively reduced breakdown of alginate hydrogel and 
development of surrounding tissue (Figure 16A). In contrast, the development of tissue 
surrounding alginate pieces and the presence of central vasculature (denoted by green 
arrows) was observable in all treatment groups containing hMSCs and/or hPL (Figure 
16B-D). Alginate-encased punctate staining was present only within the hMSC-seeded 
groups, suggesting this staining marked the remnants of delivered cells. To further 
investigate the effects of hPL incorporation on hMSC delivery, Masson’s trichrome 
staining was used to visualize granulation tissue within and surrounding the constructs. 
hPL addition was found to have qualitatively no impact on fibrotic tissue development 
within the center of the constructs (Figure 16E, F). Similarly, no effect of hPL co-
delivery on the extent of fibrous tissue lining the interior (INT) or exterior (EXT) of the 






Figure 16: Tissue Development and Morphology on Day 14 Post Implantation A) 
Minimal breakdown of alginate pieces and development of surrounding tissue was 
observed within the acellular constructs lacking co-delivered hPL (H&E; scale bar = 250 
µm). B-D) Delivery of hPL (B), hMSCs (C), or both (D) qualitatively increased tissue 
development, including vasculature, and alginate breakdown at the construct center 
(H&E; perfusion agent = black, indicated by green arrows; scale bar = 250 µm). E-H) 
hMSC-seeded constructs with (F,H) and without (E,G) co-delivered hPL contained a 
similar amount of granulation tissue present at the construct center as well as lining the 




4.3.4 Limitations of an Immunocompromised Rodent Animal Model 
 rMSCs were leveraged as a model rodent cell population in order to explore the 
response of rodent host cells to hPL exposure. Adhered hMSCs and rMSCs were 
introduced to media supplemented with FBS (16%), hPL (10%), hPL-HI (10%), or no 
serum over a 24-hr period in vitro. Little or no hMSC death was observed across all 
media treatments, as assessed via live/dead staining and fluorescent microscopy (Figure 
17A). In contrast, a large degree of rMSC death was observed in the hPL media condition 
(Figure 17B). Unexpectedly, no serum culture elicited minimal death for either cell type. 
Qualitative findings were supported by the quantification of DNA content for each 
treatment (Figure 17C). DNA content increased for all serum-supplemented hMSC 
conditions (+40-55% compared to 0-hr measurement), with no statistical difference 
between groups. rMSCs cultured in FBS (+118%) and hPL-HI (+95%) media exhibited a 
greater increase in DNA compared to equivalent hMSC groups. Conversely, rMSCs 
cultured in hPL media had decreased DNA content (-47%). Culture of either cell type 







Figure 17: Limitations of an Immunocompromised Rodent Model Adhered hMSCs 
and rMSCs were introduced to media supplemented with FBS (16%), hPL (10%), hPL-
HI (10%), or no serum over a 24-hr period in vitro. A) Little or no hMSC death was 
observed across all media treatments (live = GFP (green); dead = ethidium homodimer 
(red); scale bar = 100 µm). B) A large extent of rMSC death was observed for the hPL 
media condition only (scale bar = 100 µm). C) Quantification of DNA content supported 
qualitative microscopy observations, with hPL culture of rMSCs comprising the only 
serum-supplemented treatment to result in a DNA decrease. D) Similar concentrations of 
C5b-9 complement complex were measured for hMSCs and rMSCs (p=0.667) across all 
serum-supplemented media conditions. (* = p < 0.05 as indicated; # = p < 0.05 within 





 To determine whether the rescue in rMSC viability with hPL heat inactivation 
was due to the deactivation of complement proteins, the concentration of terminal 
complement complex (C5b-9) in each media condition at 24 hrs was measured (Figure 
17D). Acellular data (collected in a parallel experiment) illustrated that C5b-9 complexes 
formed spontaneously in hPL-, but not FBS-, supplemented media and that complement 
was capable of being further activated with the addition of HAGG. Despite noted 
differences in cell viability, similar concentrations of C5b-9 complex were measured for 
hMSCs and rMSCs in each media condition (p=0.667), suggesting complement proteins 
were not the heat-inactivated component responsible for hPL-mediated rMSC death. 
4.3.5 Limitations of a Syngeneic Rodent Animal Model 
 rPL was prepared from Lewis rats and analyzed in vitro to evaluate its similarity 
to the hPL product. hPL PDGF-AB content (56.4 pg/mL) was two orders of magnitude 
greater than that present in rPL (0.2 pg/mL), as measured via species-specific ELISA 
assays (Figure 18A). To observe whether differences in growth factor content may 
impact the response of MSCs to PL-supplemented culture, MSCs were expanded in 
same-species PL (5% or 10%) media over several passages (Figure 18B). Expansion of 
hMSCs in hPL culture promoted a dose-dependent decrease in cell DT by passage 4 
compared to FBS (16%) expansion. In contrast, expansion of rMSCs in 5% rPL media 
increased cell DT at passages 4 and 5 in comparison to FBS and 10% rPL culture, which 










Figure 18: Limitations of a Syngeneic Rodent Model rPL was prepared from Lewis 
rats and analyzed in vitro to evaluate its similarity to the hPL product. A) PDGF-AB 
content was two orders of magnitude greater for hPL (56.4 pg/mL) vs. rPL (0.2 pg/mL), 
as measured via species-specific ELISA assay B) While expansion of hMSCs in hPL-
supplemented media promoted a dose-dependent decrease in cell DT, culture of rMSCs 
in rPL-supplemented media produced an increase (5% rPL) or no change (10% rPL) in 
cell DT. (a = p < 0.05 within same media type vs. passage 2; b = p < 0.05 within same 
media type vs. passage 3; # = p < 0.05 within same passage vs. all other media 






 Given the multitude of growth factors, including mitogenic and angiogenic 
proteins, present in hPL, we expected its implementation as a pre-treatment or co-
delivery strategy to improve delivered hMSC survival. We began this research using in 
vitro analyses and observed advantages of each utilization strategy. Culture of hMSCs in 
hPL-supplemented media led to a subsequent enhancement in cell expansion even under 
serum-starved, hypoxic conditions. Incorporation of hPL into hMSC-seeded 
alginate/mesh constructs improved viable cell number over time in culture. Yet despite 
these favorable outcomes in vitro, when challenged in vivo, neither hPL utilization 
approach served to better maintain delivered hMSC number through 7 or 14 days.  
 hPL was examined as a pre-treatment strategy for hMSCs embedded within 
immediately injected and pre-cultured constructs. The rationale for investigating 
construct pre-culture was to encourage hMSC attachment to the alginate matrix prior to 
delivery, thereby improving cell survival, in part, due to a reduction in anoikis-driven cell 
death following implantation (Gilmore 2005, Lee, Choi et al. 2015). However, we 
observed a negative effect of construct pre-culture on the number of viable cells 
delivered, particularly in the case of hPL culture. This result is consistent with what some 
others have seen for large volume constructs cultured in vitro (Griffith, Miller et al. 2005, 
Davis, Schroeder et al. 2007). If a pre-culture strategy were to be reevaluated in future 
studies, use of perfusion culture or a higher serum concentration (16% FBS and 5% hPL 
were examined here) may improve viable embedded-hMSC number during this pre-
implantation period (Zhao and Ma 2005, Uzarski, Bijonowski et al. 2015). 
  Despite promising in vitro data, hPL expansion did not improve hMSC survival in 
vivo. This may in some part be attributed to challenges recapitulating the implantation 
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environment through culture conditions. Hypoxic culture in this aim leveraged a 5% 
oxygen concentration whereas the oxygen tension within our large volume constructs 
post-implantation was likely much lower (Davis, Schroeder et al. 2007). In response to 
2D hypoxic culture, hMSCs exhibit enhanced proliferation associated with an alteration 
of cellular metabolism (Boutilier 2001, Grayson, Zhao et al. 2007, Dos Santos, Andrade 
et al. 2010). It’s possible that hPL expansion impacts hMSC metabolic phenotype in a 
manner that impedes adaptation to severely hypoxic conditions (Griffiths, Baraniak et al. 
2013). 
 The motivation to evaluate hPL as a co-delivery strategy was its capacity to 
provide both physical and biochemical cues. Within cell-contractible matrices, physical 
cues are known to impact many aspects of hMSC phenotype including proliferation and 
morphology (Guilak, Cohen et al. 2009, Khetan, Guvendiren et al. 2013, Lee, Abdeen et 
al. 2013, Zhang and Kilian 2013). The fibrinogen content of hPL allows it to form a 
hydrogel that has demonstrated advantages over the use of tissue culture plastic for 
hMSC expansion (Walenda, Hemeda et al. 2012). Our studies integrated hPL within an 
alginate hydrogel backbone in order to achieve the benefits of an hPL matrix while 
maintaining construct bulk, as preliminary studies had found the contractibility of pure 
hPL hydrogels to result in a severely reduced construct volume with hMSC culture (data 
not shown). However, although we anticipated the addition of a fibrin network to impact 
alginate-embedded hMSC morphology through promotion of cell spreading, we instead 
observed that cells were largely rounded in both treatment groups (Bensaid, Triffitt et al. 
2003). We hypothesized this lack of morphological change could be due to a deficiency 
of hPL content (20% v/v) or calcium crosslinker. To explore whether the calcium sulfate 
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(80 mM) added to our hydrogels was sufficient to overwhelm the concentration of acid 
citrate dextrose, a calcium chelator, in order to crosslink both the alginate and hPL 
constituents, additional calcium was added during the crosslinking protocol (100 mM 
total). Increased calcium concentration did not result in an hPL-induced hMSC 
morphological change (data not shown), indicating that the low hPL concentration, rather 
than calcium content, may have been responsible for a lack of hMSC spreading. 
 Despite no evidence supporting a modulated physical environment with hPL co-
delivery, achievement of biochemical manipulation was confirmed following a PDGF-
AB release study. PDGF-AB underwent burst release, with greater than 50% release 
through 12 hrs in culture, from acellular and hMSC-seeded hPL-containing constructs. 
Cumulative PDGF-AB release from cell-containing hydrogels was lower, suggesting that 
hMSCs were metabolizing the incorporated growth factor. This finding is consistent with 
the known role PDGF signaling plays in various aspects of hMSC behavior including 
growth, migration, and differentiation (Ng, Boucher et al. 2008). Furthermore, the 
baseline activity of hMSC PDGF receptors may have been augmented due to VEGF-A 
present in the hPL (Ball, Shuttleworth et al. 2007, Italiano, Richardson et al. 2008, Baik, 
Lim et al. 2014). Unsurprisingly, as PDGF is only a minor component of the hMSC 
secretome, cell-seeded constructs without incorporated hPL failed to release substantial 
levels of PDGF-AB in this study (Kinnaird, Stabile et al. 2004, Ohnishi, Yasuda et al. 
2007, Chiellini, Cochet et al. 2008). 
 In addition to hPL incorporation acting through the delivered hMSCs, we 
anticipated that an hPL-releasing therapeutic would drive a favorable host cell response 
as well. Due to its VEGF content, we hypothesized that hPL incorporation would 
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promote construct vasculature (Folkman 2007, Italiano, Richardson et al. 2008). 
Additionally, although we’ve previously identified no effect of cell delivery alone on 
construct vasculature within system, it was projected that hMSC delivery in conjunction 
with hPL may increase construct vasculature in a synergistic manner (Ball, Shuttleworth 
et al. 2007, Allen, Gazit et al. 2014). However, we saw no effect of either implanted 
component on construct vasculature volume. One potential explanation for this is the 
complex mixture of pro- and anti-angiogenic factors contained within hPL (Italiano, 
Richardson et al. 2008). The occurrence of hPL-elicited rMSC death, as identified by the 
in vitro studies discussed below, represents a likely contributing factor that was not yet 
recognized at the time of in vivo delivery.  
 To better isolate the potential interaction between delivered hPL and host cells, 
we studied the effect of hPL-culture on rMSCs in vitro. Strikingly, exposure of rMSCs to 
hPL produced dramatic cell death, a phenomenon attributable to a heat labile hPL 
component. It was suspected that membrane attack complex (MAC) formation was 
responsible for this effect due to the high concentration of complement proteins present 
in hPL (Romanella, Aminian et al. 1997, Blair and Flaumenhaft 2009, Rubio-Azpeitia 
and Andia 2014, Morgan 2015). However, MAC concentration was found to be similar 
across all hPL and hPL-HI culture conditions, indicating that complement-mediated cell 
lysis was not responsible for hPL-induced rMSC death. Complement-independent 
mechanisms that may have played a role in this xenogeneic response include cold 
agglutinin- and antithymocyte globulin-mediated processes (Salama, Gottsche et al. 1988, 
Zand, Vo et al. 2005). Irrespective of mechanism, rMSC death in response to hPL 
exposure in vitro indicated that an immunocompromised rodent model (Nude rats) was 
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not sufficient to ameliorate xenogeneic complications in the pre-clinical testing of hPL. 
 The potential for leveraging a syngeneic model (Lewis rats) for hPL therapeutic 
efficacy was subsequently explored. First, the hPL and rPL products were examined for 
growth factor quantity. The PDGF-AB content of rPL was found to be two orders of 
magnitude lower than that of hPL, rendering rPL a fundamentally distinct product. This 
observation is compatible with previously published data showing greater concentrations 
of PDGF-AA, PDGF-AB, PDGF-BB, and TGF-β in human platelet-rich plasma (PRP) 
compared to that derived from rat or goat (van den Dolder, Mooren et al. 2006). 
Secondly, the effect of rPL-supplemented culture on rMSC expansion was examined and 
shown not to produce the same beneficial effect on cell doubling time (DT) as observed 
for hPL-supplemented hMSC expansion. However, rMSC DT with increased rPL 
concentration (10% vs. 5% v/v) was comparable to that of FBS culture, suggesting no 
disadvantage of using rPL as a serum substitute to FBS culture. Overall, the heightened 
potency of human platelet-derived product may be physiologically rationalized by species 
variability in circulating platelet concentration, with rodents exhibiting a baseline 
quantity 5-fold that of humans (1000 vs. 200 x106 platelets/mL) (van den Dolder, Mooren 
et al. 2006). 
 To summarize the findings for this thesis aim, significant challenges in the pre-
clinical testing of hPL as an hMSC-based delivery strategy were identified. Despite 
encouraging results in culture, the utility of hPL as either a pre-treatment or co-delivery 
strategy was investigated within an immunocompromised rodent model and found to 
serve no benefits regarding hMSC survival or construct vascularization. Upon follow-up 
inspection using a model rodent cell type in vitro, exposure of rMSCs to hPL-
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supplemented media resulted in dramatic cell death, indicating a major limitation of 
delivering hPL to a rodent model, irrespective of immune system deficiency. In 
evaluating whether rPL could recapitulate the potential therapeutic efficacy of hPL 
delivery, rPL was found to be deficient in growth factor content as well as the capacity to 
potentiate rMSC expansion. These results highlight concerns of xenogenicity and 




CHAPTER 5  MESENCHYMAL STEM CELL AGGREGATION 
FOR LARGE BONE DEFECT REPAIR 
 
5.1 Introduction 
The repair of bone tissue is finely tuned to its local inflammatory environment. 
Injury stimulates an array of inflammatory signaling cascades, the factors and cytokines 
of which have been interrogated using knockout animal models and antagonist delivery 
(Mountziaris, Spicer et al. 2011, Thomas and Puleo 2011). These studies have 
highlighted the unique temporal role of inflammatory signals such as tumor necrosis 
factor alpha (TNF-α), interleukin 6 (IL-6), and prostaglandin E2 (PGE2) during this 
regenerative period (Chambers, Fox et al. 1999, Mountziaris and Mikos 2008, Blanchard, 
Duplomb et al. 2009, Thomas and Puleo 2011).  
 While cell-based treatments for large bone defect repair hold promise, the long-
term viability of these implants has proven difficult to maintain. It is possible that the 
potency of cell-based therapeutics could be improved by engineering delivered cells to 
secrete paracrine factors necessary for the healing process. Human mesenchymal stem 
cells (hMSCs) have inherent anti-inflammatory properties (Iyer and Rojas 2008, Ankrum, 
Ong et al. 2014). Recent work has found that this hMSC immunomodulatory potential 
can be augmented via the formation of these cells into three-dimensional aggregates 
(Bartosh, Ylostalo et al. 2010, Zimmermann and McDevitt 2014). Spheroid culture 
increased the production of immunomodulatory factors, including IL-6 and PGE2, in 
comparison to hMSCs cultured in monolayer. Additionally, exposure of hMSC spheroids 
to pro-inflammatory cytokines, as found within injured tissue, further enhanced this 
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factor secretion.  
 Aside from enriched anti-inflammatory capacity, MSC spheroids have 
demonstrated favorable survival, angiogenic, and osteogenic properties. Association of 
MSCs as spheroids has been shown to decrease cell apoptosis and increase angiogenic 
factor expression in vitro (Bhang, Cho et al. 2011, Murphy, Fang et al. 2014). In 
comparison to dissociated MSCs, cell aggregates exhibited improved osteogenic potential 
in vitro and in vivo (Wang, Itaka et al. 2009, Murphy, Fang et al. 2014, Yamaguchi, Ohno 
et al. 2014). However, although delivery of MSC aggregates demonstrated efficacy 
within one orthotopic bone repair model (a calvarial defect), this strategy had not been 
challenged within a large volume, critically-sized bone injury (Yamaguchi, Ohno et al. 
2014). 
 The effects of MSC aggregation on angiogenic and osteogenic potential positions 
spheroid delivery as a promising cell-based platform for large bone defect repair. The 
objective of this aim was to quantify the effects of MSC aggregation on cell survival and 
cell-based bone regeneration. We hypothesized that delivery of MSC spheroids would 
potentiate MSC survival and guided bone regeneration in comparison to single cell 
delivery. To test this hypothesis, we evaluated the effects of MSC aggregation using 
alginate/mesh constructs delivered subcutaneously or to critically-sized femoral defects. 
Building on the discussion of pre-clinical testbeds prompted by our human platelet lysate 
(hPL) studies, we leveraged both immunocompromised and syngeneic rodent models. 
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5.2 Materials and Methods 
5.2.1 MSC Culture and Aggregate Formation 
 Bone marrow-derived hMSCs were purchased from the Texas A&M University 
Health Science Center and cultured as previously described (Allen, Gazit et al. 2014). 
Briefly, two donor cell lines were expanded in Minimum Essential Medium alpha 
(αMEM) containing 16% v/v fetal bovine serum (FBS; Atlanta Biologicals; 
Lawrenceville, GA) and 100 units/mL penicillin/100 µg/mL streptomycin/2 mM L-
glutamine (PSL; Invitrogen; Carlsbad, CA) at 37ºC and 5% CO2. At passage 2, cells were 
detached using 0.25% trypsin-EDTA (Invitrogen) and combined 1:1 to form a pooled 
hMSC population. Lewis rat MSCs (rMSCs), characterized for multipotency, were 
purchased (Sciencell Research Laboratories; Carlsbad, CA) and expanded until passage 2 
in similar culture conditions. Following expansion, MSCs to be used in bioluminescent 
imaging (BLI) studies were labeled via lentiviral co-transduction for constitutive 
expression of green fluorescent protein (GFP) and firefly luciferase (Luc) as previously 
reported (Sun, Lee et al. 2009, Sheyn, Kallai et al. 2011). To produce MSC aggregates, 
cells were seeded in 400-µm agarose micro-wells as described previously (Ungrin, Joshi 
et al. 2008, Zimmermann and McDevitt 2014). Briefly, MSCs were added to micro-well 
inserts, centrifuged for 5 minutes at 200g, and left to form aggregates (500 cells/spheroid) 
over 14-18 hrs. To characterize rMSC aggregate secretion and intracellular alkaline 
phosphatase (ALP) activity, a modified protocol to that conducted previously on hMSC 
aggregates was implemented (Zimmermann and McDevitt 2014). Culture media (n=6) at 
24 hrs was collected from adherent “2D” rMSCs (1,300 cells/cm2) as well as rMSC 
aggregates (0.3 x106 cells/100 mm dish) cultured on a rotary orbital shaker. Media 
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concentrations of rat interleukin 6 (IL-6) and prostaglandin E2 (PGE2) were measured by 
ELISA assays (R&D Systems; Minneapolis, MN) and normalized to DNA content 
quantified via the Quant-iT PicoGreen dsDNA Kit (Molecular Probes; Eugene, OR). 
ALP activity (n=6) was measured by incubation of intracellular contents in 20mM 
phosphatase substrate (p-NPP; Sigma-Aldrich; St. Louis, MO). 
5.2.2 Alginate Embedding of hMSCs 
 hMSCs were embedded within RGD-functionalized alginate hydrogel (2% w/v; 
FMC BioPolymer; Ewing, NJ) in either single cell and aggregate form using a dual-
syringe mixing technique with subsequent calcium sulfate (8.4 mg/mL; Sigma-Aldrich) 
cross-linking (Allen, Gazit et al. 2014). To verify maintenance of cell viability and 
spheroid structure following alginate incorporation and syringe injection, hMSC 
aggregates were embedded at densities of 0.5 and 2.0 x106 cells/150 µL (n=3). Resultant 
hydrogel was stained using a LIVE/DEAD Kit (Invitrogen) and imaged by inverted 
microscope (Axio Observer; Carl Zeiss; Thornwood, NY). To evaluate BLI signal vs. cell 
number correlation, individual and aggregated GFP/Luc hMSCs were embedded at 
densities of 0, 0.5, and 1.0 x106 cells/150 µL (n=6) and imaged using an IVIS Lumina 
machine (Caliper Life Sciences; Hopkinton, MA). Beetle luciferin (Fisher Scientific; 
Hampton, NH) was added to the culture media (0.21 mg/mL) 20 minutes prior to image 
acquisition (5 second exposure; 12.5 cm field of view). Living Image software version 
3.2 (Caliper Life Sciences) was used to demarcate a circular region of interest (ROI) 
centered over each well and BLI counts were normalized to exposure time and ROI area. 
A subset of aggregate-seeded hydrogels (n=3) were cultured over 1 week, sectioned using 
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a CryoStar NX70 cryostat (Fisher Scientific), stained with lactate dehydrogenase (LDH), 
and imaged (Zeiss). 
5.2.3 Alginate Embedding of rMSCs 
rMSC single cells or aggregates were similarly embedded within alginate 
hydrogel (2% w/v) along with added PBS (control) or perfluorotributylamine (10% w/v; 
PFTBA; Sigma-Aldrich) emulsion. Emulsions were prepared by sonication of PFTBA 
and phosphate-buffered saline (PBS; 2:3 ratio) or PBS alone with Lipoid E 80 (0.1 g/mL; 
Lipoid; Newark, NJ) using a Vibra-Cell VCX130PB (Sonics & Materials; Newtown, CT) 
for 2 minutes at 31%. Prior to alginate cross-linking, all rMSC groups and associated 
acellular controls received identical emulsion concentrations to produce 0% and 10% 
PFTBA hydrogels. GFP/Luc rMSC-seeded alginate with single or aggregated cells (0.5 
x106 cells/150 µL) and 0% or 10% PFTBA was injected into electrospun, 
polycaprolactone (PCL) mesh tubes (150 µL/construct) and cultured over 4 days under 
hypoxic conditions (3% O2). To quantify change in viable cell number, longitudinal BLI 
was performed on Days 0, 2, and 4 using the protocol described in sub-section 5.2.2 
(n=8) with culture media (2 mL/well) replaced following each timepoint. In preparation 
for segmental defect delivery, singular or aggregated rMSCs were seeded at a density of 
0 (acellular) or 1.0 x106 cells/150 µL, with or without PFTBA, and recombinant human 
BMP-2 (1.5 µg/150 µL; rhBMP-2). Resultant hydrogels (n=4) were cultured in mesh 
tubes with media collected and replaced on Days 1, 4, and 7. Conditioned media was 
measured for BMP-2 content using an ELISA assay (R&D Systems) and examined using 
a previously established ALP induction protocol (Wiemann, Rumpf et al. 2001, Priddy, 
Chaudhuri et al. 2014). Briefly, mouse clonal pre-osteoblasts (MC3T3-E1; American 
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Type Culture Collection; Manassas, VA) were plated at confluence (1,300 cells/cm2) and 
culture in the construct-conditioned media. After 3 days, MC3T3-E1 cells were washed, 
fixed, and incubated in 7.6mM p-NPP to determine ALP activity. Normalized ALP 
activity was calculated using DNA content, measured as previously described in sub-
section 5.2.1.  
5.2.4 Subcutaneous Implantation 
 Surgical implantation was conducted in accordance with the Georgia Institute of 
Technology IACUC protocol #A13023 as described previously (Allen, Gazit et al. 2014). 
Alginate hydrogel seeded with singular or aggregated GFP/Luc hMSCs at a density of 0.5 
x106 cells/150 µL (n=5) were stored at 4°C for 1-4 hrs prior to delivery, at which point 
hydrogel was injected into PCL tubes (150 µL/construct) and implanted within 11-week-
old female, athymic Nude rats (Charles River Labs; Wilmington, MA). As previously 
described, two dorsal incisions were made to prepare four subcutaneous pockets per 
animal. rMSC-seeded hydrogels were implanted in a similar manner within 11-week-old 
male, inbred Lewis rats (Harlan Laboratories; Indianapolis, IN). GFP/Luc and unlabeled 
rMSCs were combined at a 2:1 ratio prior to alginate embedding. Constructs with 
singular or aggregated rMSCs at a density of 0 (acellular) or 0.5 x106 cells/150 µL and 
with or without PFTBA were delivered (n=7-10). 
5.2.5 Subcutaneous BLI, Vascular, and Histological Analyses 
Nude rats underwent longitudinal BLI at Days 0, 1, 3, 5, 7, and 14 post-
operatively using a previously established protocol (Allen, Gazit et al. 2014). 
Anesthetized rats received a subcutaneous injection of 300 µL luciferin (21 mg/mL in 
saline) at a distance of 2-4 mm from each construct site. The animals were scanned on 
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either side 30 minutes post luciferin injection (10 second exposure; 12.5 cm field of 
view) and images were evaluated using a 4 cm2 elliptical ROI. Following Day 14 BLI, 
Nude rats underwent vascular perfusion using serially applied saline (0.9% w/v), 
papaverin hydrochloride (0.4% w/v in saline), neutral buffered formalin (10% v/v), and 
the radiopaque contrast agent Microfil (Flow Tech; Carver, MA) solutions. Explants were 
excised and imaged via microcomputed tomography (µCT) scans on a MicroCT42 
(Scanco Medical; Brüttisellen, Switzerland) at 55kVp, 145µA, and a 12µm voxel size. 
Acquired slices were contoured and segmented using a low-pass Gaussian filter 
(sigma=1.2, support=2) to evaluate vascular volume within the construct interior alone. 
Following µCT scans, explants were paraffin embedded, histologically sectioned via 
microtome (Microm; Walldorf, Germany), stained with Masson’s trichrome or DAPI, 
and imaged (Zeiss). Lewis rats underwent similar examination with longitudinal BLI 
performed on Days 0, 1, 7, and 14 followed by takedown for vascular and histological 
analyses on Day 14. 
5.2.6 Segmental Defect Implantation 
 Segmental defect surgeries were conducted in accordance with the Georgia 
Institute of Technology IACUC protocol #A14037. Due to a lengthened surgical timeline 
in comparison to subcutaneous implantation, the effect of 4°C syringe incubation on 
alginate-embedded MSC viability was examined prior to delivery. Single and spheroid 
MSCs at 1.0 x106 cells/150 µL alginate (n=3) were incubated for 0, 4, or 8 hrs at 4°C and 
subsequently injected, stained via LIVE/DEAD Kit (Invitrogen), and imaged (Zeiss). 
rMSC-seeded hydrogels containing emulsions were analyzed using a cell metabolic assay 
(n=3) due to imaging challenges resulting from altered gel opacity. Singular or 
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aggregated rMSC-seeded hydrogels containing no, PBS, or PFTBA emulsion and having 
undergone a 0- or 8-hr syringe incubation at 4°C were cultured for 48 hrs and assessed by 
CellTiter-Blue viability assay (Promega; Madison, WI) according to manufacturer 
recommendation. On each date of surgery, bilateral femoral defects were created in 13-
week-old rats as previously described (Oest, Dupont et al. 2007, Kolambkar, Boerckel et 
al. 2011). Briefly, an 8-mm critically-sized defect was created in the mid-diaphysis of 
each femur following attachment of a polysulfone fixation plate to provide limb 
stabilization. Injuries were treated with a PCL mesh surrounding each defect followed by 
injection of alginate hydrogel (150 µL) incubated for 1-8 hrs at 4°C prior to delivery. 
Nude rats received acellular, single cell, or aggregated hMSC-seeded (1.0 x106 cells/150 
µL) alginate containing a 2-µg dose of rhBMP-2. A treatment group containing hMSC 
aggregate-seeded alginate without rhBMP-2 was included as well. Lewis rat defects were 
treated with acellular, single cell, or aggregated rMSC-seeded (1.0 x106 cells/150 µL) 
alginate containing PBS or PFTBA emulsion and a 1.5-µg dose of rhBMP-2. A subset of 
Lewis rat defects received rMSCs labeled with DiI stain (Invitrogen) to facilitate 
downstream histological analysis. 
5.2.7 Segmental Defect Radiography and µCT Analyses  
 Longitudinal bone regeneration for all rats was assessed qualitatively via 
radiography (Faxitron MX-20 Digital; Faxitron Bioptics; Tucson, AZ) at 4, 8, and 12 
weeks post-operatively. At the same timepoints, Nude rats also received quantitative 
evaluation of bone formation by µCT (VivaCT40; Scanco Medical) at 55kVp, 145µA, 
and a 38.9µm voxel size (n=7-10). Regenerated bone volume was analyzed using a 
volume of interest (VOI) consisting of 100 slices within the defect center. Lewis rats 
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received ex vivo µCT evaluation due to their prohibitive size. Explanted femurs were 
scanned at 55kVp, 145µA, and a 21µm voxel size then evaluated using a VOI consisting 
of 280 slices (n=6-9). 
5.2.8 Segmental Defect Biomechanical and Histological Analyses 
 Femurs were explanted at 12 week post-operatively and underwent torsional 
testing to failure as previously reported (Oest, Dupont et al. 2007). Briefly, bone ends 
were potted in Wood’s metal (Alfa Aesar; Ward Hill, MA) following soft tissue and 
fixation plate removal. Using an ELF 3200 machine (Bose ElectroForce Systems Group; 
Eden Prairie, MN), samples were displaced at 3 °/s. Maximum torque and torsional 
stiffness were calculated for the Nude (n=5-7) and Lewis (n=6-9) rat explants. Following 
biomechanical testing, Lewis rat defects were removed, decalcified (Cal-ExII; Fisher 
Scientific), and paraffin embedded. Samples were sectioned via microtome (Microm), 
stained with safranin O (SafO), and imaged (Zeiss). 
5.2.9 Statistical Analysis 
Values are displayed as mean +/- standard error of mean (SEM) unless otherwise 
stated with statistical significance defined by p<0.05. Data were analyzed using two-way 
analyses of variance (ANOVA) with Tukey post hoc comparisons within the Minitab 
software (State College, PA). 
 
5.3 Results 
5.3.1 Subcutaneous Implantation of hMSC Aggregates in Nude Rats 
 In preparation for in vivo delivery, in vitro characterization of hMSC aggregates 
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incorporated into RGD-alginate hydrogels was performed. It was found that hMSCs 
aggregates maintained their viability and structure following the alginate cross-linking 
and syringe injection procedures (Figure 19A). Correlation of bioluminescent imaging 
(BLI) signal vs. viable cell number for GFP/Luc hMSC aggregates was observed to be 
linear (r2 = 0.75) and statistically similar to that of GFP/Luc hMSCs embedded as single 
cells (Figure 19B). Culture of these constructs over 1 week illustrated the breakup of 






Figure 19: Embedding of hMSC Aggregates in Alginate Hydrogel A) hMSC 
aggregates (live = GFP (green); dead = ethidium homodimer (red)) maintained viability 
and structure following alginate embedding at densities of 0.5 (left) and 2.0 (right) x106 
cells/150 µL (scale bar = 100 µm). B) In vitro BLI counts vs. viable cell number for 
aggregate-seeded hydrogels displayed a linear correlation (r2 = 0.75) similar to that of 
constructs seeded with single hMSCs (r2 = 0.99). C) Aggregated hMSCs migrated as 
single cells within the alginate hydrogel over 1 week of culture, as assessed by LDH 
staining (scale bar = 100 µm). 
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 Alginate/mesh constructs seeded with dissociated or aggregated GFP/Luc hMSCs 
were implanted subcutaneously in Nude rats and monitored for cell survival via BLI. 
hMSC aggregation had no adverse effect on viable cell number, with both groups 
exhibiting 1-2% survival through 14 days post-operatively (Figure 20). On Day 14, 
vascular perfusion and histological analyses were performed to examine tissue 
development contiguous to the constructs. There was no effect of aggregate delivery on 
construct vascular volume (Figure 21A) or gross vessel morphology, as assessed 
qualitatively via representative µCT vasculature reconstructions (Figure 21B). Masson’s 
trichrome staining revealed the presence of alginate pieces (dashed outline), fibrotic 
tissue (yellow arrows), and alginate-enclosed ECM pockets (green arrows) present within 
both treatment groups (Figure 21C). Morphology of ECM pockets embedded within the 
alginate pieces was observed to be qualitatively distinct between the treatment groups, 
with single cell delivery resulting in a more even distribution of pockets throughout the 
construct. In contrast, aggregate-seeded samples contained a more heterogeneous 
distribution of ECM pockets, including those that appeared to be branching (red arrows) 







Figure 20: Effect of hMSC Aggregation on Viability through 14 Days In Vivo A) 
Representative BLI heatmaps illustrate similarly maintained viability for hMSCs 
delivered in single cell and aggregated form subcutaneously to Nude rats over 14 Days. 
B) Quantification of BLI signal found no significant effect of aggregate delivery on 







Figure 21: Effect of hMSC Aggregation on Construct Composition at 14 Days A) 
Construct vascular volume at Day 14 was unaffected by hMSC aggregation. B) Vascular 
reconstructions of representative single cell (left) and aggregate (right) samples colored 
to indicate vessel diameter demonstrate no qualitative difference in vessel morphology. 
C) Irrespective of treatment, explants contained alginate pieces (outlined in red, dashed 
lines) surrounded by fibrotic tissue (yellow arrows), as visualized using Masson’s 
trichrome staining. Morphology of alginate-embedded ECM pockets differed between 
treatments, with single cell delivery resulting in a more qualitatively even distribution 
(green arrows) while aggregate samples contained multi-node (pink arrows) and 
branching (red arrows) pockets as well as regions void of ECM pockets (not shown). 
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5.3.2 hMSC Aggregation for Large Bone Defect Repair in Nude Rats 
 To examine the effect of hMSC aggregation on cell-based bone regeneration, 
bilateral critically-sized defects were created in Nude rats and treated with alginate/mesh 
constructs containing a 2-µg dose of BMP-2 and either no cells, single hMSCs, or 
aggregated hMSCs. Additionally, an aggregates treatment containing no BMP-2 was 
delivered to observe the extent of aggregate-mediated bone defect repair in the absence of 
co-delivered osteoinductive stimulus. Longitudinal in vivo µCT at 4, 8, and 12 weeks 
post-operatively revealed no difference in regenerated bone volume across BMP-2-
containing treatments (Figure 22A). However, the absence of BMP-2 delivery was found 
to attenuate bone regeneration. Biomechanical testing data exhibited increased variability 
compared to bone volume results, with no significant effect of hMSC delivery or BMP-2 





Figure 22: Effect of hMSC Delivery for Large Bone Defect Repair in Nude Rats A) 
Longitudinal µCT measurement revealed no effect of hMSC delivery, either as single 
cells or aggregates, on regenerate bone volume. However, the lack of a co-delivered 
BMP-2 alongside hMSC aggregates (“Aggregates” group) resulted in a significantly 
diminished amount of bone tissue. B) Maximum torque of the explanted femurs was 
highly variable and not significantly affected by method of hMSC delivery (p=0.985) nor 
BMP-2 treatment (p=0.090). C) Similarly, neither cell group (p=0.942) nor BMP-2 dose 




 Based on qualitative observations, a high degree of animal-to-animal variability 
was suspected in the aforementioned study. To explore this phenomenon, the average 
regenerated bone volume for each Nude rat receiving bilateral BMP-2-containing 
treatments was charted against the average BMP-2-mediated regenerated bone volume at 
each post-operative timepoint of 4, 8, and 12 weeks (Figure 23A-C). Qualitatively, 
subsets of animals were found to be either highly responsive or insensitive to BMP-2-
mediated bone defect repair. To statistically analyze this finding, p-values for the 
“animal” and “treatment” variables were calculated for several data sets (Figure 23D). 
Applying this analysis to Nude rats receiving bilateral BMP-2-containing treatments (the 
illustrated data set), the “animal” variable alone was determined a significant predictor of 
regenerated bone volume. For historical comparison, identical analysis performed on 
results from a bilateral study in Sprague Dawley rats showed no significant effect of 
biological variability (p=0.617). The extent of biological variability observed within this 
Nude rat study motivated subsequent investigation of MSC aggregation within a 






Figure 23: Biological Variability within the Nude Rat Model A-C) The average 
regenerated bone volume (error bars = standard deviation) for Nude rats receiving 
bilateral BMP-2-containing treatments was charted against the overall regenerated bone 
volume average (excluding “Aggregates” group) at each post-operative timepoint of 4 
(A), 8 (B), and 12 (C) weeks. Qualitatively, some animals appeared to be either highly 
responsive (#62, 72) or insensitive (#57, 59) to BMP-2-mediated defect repair. D) 
Statistical analysis via two-way ANOVA revealed a significant effect of animal 
(p=0.021), but not treatment (p=0.768), on regenerated bone volume for the 
aforementioned sample subset. In contrast, a similar bilateral segmental defect study 




5.3.3 In Vitro Characterization of rMSC Aggregates 
 The same protocol employed for hMSC aggregate formation was effective to 
produce rMSC aggregates. Spheroids formed over 14 hrs when rMSCs were seeded in 
agar micro-wells (Figure 24A). Up-regulated immunomodulatory factor secretion, as 
previously observed for hMSC aggregates, arose with rMSC aggregation as well. rMSC 
aggregates exhibited increased production of IL-6 and PGE2 over 24 hrs in comparison 
to cells plated in 2D (Figure 24B). Additionally, intracellular ALP activity was 
potentiated by rMSC aggregation (Figure 24C). 
 Motivated by the nominal survival rate achieved with hMSC delivery (Figure 20), 
the effect of co-delivered PFTBA, a synthetic oxygen carrier, was explored for rMSC 
implantation. In preparation for in vivo delivery, the effect of PFTBA addition (10% w/v) 
to alginate/mesh constructs on embedded GFP/Luc rMSC survival was investigated in 
vitro under hypoxic conditions (3% O2). Quantification of viable cell number via 
longitudinal BLI revealed an effect of cell presentation (single cells vs. aggregates), but 
not PFTBA incorporation, on absolute BLI signal through 4 days (Figure 25A). Likewise, 
analysis of normalized BLI found improved maintenance of rMSC viability for single cell 
(SC) groups and no effect of PFTBA addition (Figure 25B). Given the differences 
between an in vivo vs. in vitro hypoxic environment and the finding that PFTBA co-
delivery had no negative effect on embedded-rMSC viability, we chose to continue 







Figure 24: Formation and In Vitro Characterization of rMSC A) Similar to hMSCs, 
rMSCs seeded in agar micro-wells formed aggregates (500 cells/spheroid) over 14 hrs. B) 
rMSCs exhibited increased secretion of the immunomodulatory factors IL-6 and PGE2 
over 24 hrs in comparison to rMSCs plated in 2D. C) Intracellular ALP activity 




Figure 25: Hypoxic Culture of rMSCs within Alginate Hydrogels Single cell (SC) and 
aggregated (AG) rMSCs were embedded within alginate hydrogels with (+) or without (-) 
the synthetic oxygen carrier PFTBA. Longitudinal BLI was conducted to monitor cell 
viability throughout 4 days of culture at hypoxic (3% O2) conditions. A) Absolute BLI 
signal demonstrated an overall effect of cell group (SC vs. AG), but not PFTBA 
incorporation, and no individual differences between treatments. B) Normalized BLI 
revealed better-maintained viability for single cell groups and no effect of PFTBA 
addition. (* = p < 0.05 as indicated; $ = p < 0.05 within treatment vs. Day 2; # = p < 0.05 




5.3.4 Subcutaneous Implantation of rMSC Aggregates in Lewis Rats  
 Single cell (SC) and aggregate (AG) seeded alginate/mesh constructs with (+) or 
without (-) PFTBA as well as acellular (Acell) controls were implanted subcutaneously in 
Lewis rats and monitored via BLI. Representative heatmaps illustrated a qualitative 
decrease in BLI signal for all rMSC delivery groups over 14 days post-implantation 
(Figure 26A). Constructs seeded with single rMSCs displayed a high degree of 
variability, with several samples exhibiting a marked increase in viable cell number 
between Days 0 and 1 (Figure 26B). Absolute BLI measurements showed that a similar 
number of viable cells were delivered across all rMSC-containing treatments (Figure 
27A). Additionally, the negligible signal for acellular samples on Day 0 indicated 
minimal background noise arising from the BLI technique. Normalized BLI 
demonstrated a significant overall effect of cell presentation (pSCvs.AG=0.009), but not 
PFTBA incorporation (pPFTBA=0.075), on in vivo survival (Figure 27B). Single rMSC 
delivery in the absence of PFTBA (SC-) resulted in the greatest viable cell number on 
Day 1 post-operatively. Although the majority of acellular implants displayed negligible 
BLI signal throughout the study duration (Figure 28A), several Acell- constructs 
increased in BLI signal over time (Figure 28B). Interestingly, this phenomenon had not 
been observed in former hMSC delivery experiments and was not, in the present study, 







Figure 26: BLI Heatmaps of rMSCs Implanted Subcutaneously through 14 Days 
Single cell (SC) and aggregated (AG) rMSCs were delivered within alginate/mesh 
constructs with (+) or without (-) PFTBA oxygen carrier. A) All groups displayed a 
qualitative decrease in BLI signal through 14 days, indicative of a post-operative drop in 
viable cell number over time. B) Constructs seeded with single rMSCs exhibited high 
variability, with some samples increasing in signal between Days 0 and 1. Samples from 






Figure 27: Longitudinal BLI of Subcutaneously Implanted rMSCs Acellular (Acell), 
single cell (SC), and aggregate (AG) treatments with (+) or without (-) PFTBA were 
delivered to Lewis rats and longitudinally monitored through 14 days using BLI. A) 
Absolute BLI measurements showed that a similar number of viable cells was delivered 
across all rMSC-containing treatments. Additionally, the low signal for acellular samples 
(Acell-, Acell+) on Day 0 indicated minimal background signal produced by the BLI 
technique. B) Normalized BLI demonstrated a significant effect of cell presentation 
(pSCvs.AG=0.009), but not PFTBA incorporation (pPFTBA=0.075), on in vivo survival. 
Individual comparisons between treatments and timepoints revealed an increase in viable 
cell number for the SC- treatment at Day 1. (# = p < 0.05 within timepoint vs. all other 







Figure 28: Longitudinal BLI of Acellular Constructs through 14 Days In Vivo A) 
Representative BLI heatmaps illustrate that the majority of acellular implants displayed 
negligible signal throughout the implantation duration. B) However, several acellular 
samples increased in BLI signal over time, as shown by heatmap images and normalized 
BLI signal (note Acell- value on Day 7). This behavior was not observed previously in 
Nude rat studies and no correlation was found between the BLI signal of Acell treatments 




 Examining tissue composition within the subcutaneous explants, there was no 
qualitative effect of rMSC or PFTBA delivery on construct vessel size distribution or 
placement through the construct (Figure 29A). Upon quantification, these experimental 
parameters had no overall effect on construct vascular volume (Figure 29B). In 
comparing individual treatment groups, single rMSC seeded constructs without PFTBA 
(SC-) contained more vasculature than acellular, PFTBA-containing (Acell+) constructs. 
Histological examination via H&E staining revealed a similar extent of residual alginate 
pieces surrounded by granulation tissue across all experimental groups (Figure 30A). 
Consistent with bioluminescent data, fluorescence microscopy confirmed the retention of 
a delivered rMSC population within constructs initially seeded with singular and 
aggregated cells (Figure 30B). Aggregation may have promoted rMSC migration, as 
evidenced by single cells appearing to be retained within alginate pieces through 14 days 






Figure 29: Effect of rMSC Aggregation on Construct Vasculature at 14 Days A) 
Vascular reconstructions illustrate vessel diameter distribution in representative images 
from each treatment group. Qualitatively, no gross effects of cell delivery group or 
PFTBA addition were apparent. B) Quantification of construct vascular volume found no 
overall effect of rMSC or PFTBA delivery. However, single cells constructs without co-








Figure 30: Effect of rMSC Aggregation on Construct Composition at 14 Days A) All 
treatment groups contained a similar extent of residual alginate pieces (red asterisks) 
surrounded by granulation tissue, as visualized through H&E staining (0% PFTBA 
groups shown). B) Fluorescent microscopy revealed the presence and distribution of 
delivered rMSCs (rMSCs = red (DiI); all nuclei = blue (DAPI)). Implanted single cells 
appeared to be retained within alginate pieces and away from regions of high cellularity. 
rMSCs delivered as spheroids remained clustered, although exhibiting a diameter greater 
than that of the initially implanted structures (~175 µm vs. ~100 µm), indicating the 




5.3.5 Release of BMP-2 from rMSC-Seeded Constructs In Vitro 
 In preparation to interrogate within the segmental defect model, the effect of 
rMSC and PFTBA incorporation on co-delivered BMP-2 release was quantified in vitro. 
Alginate/mesh constructs were prepared with no (Acell), singular (SC), or aggregated 
(AG) rMSCs, with (+) or without (-) PFTBA, and a 1.5-µg dose of BMP-2. Conditioned 
media was collected from cultured constructs on Days 1, 4, and 7 to measure (i) BMP-2 
content and (ii) the capacity for ALP activity induction in a pre-osteoblast cell line 
(MC3T3-E1). Over the first 24 hrs of culture, constructs across all groups released 
comparable amounts of BMP-2 (Figure 31A). However, following this initial period, 
more BMP-2 was released from acellular constructs than those seeded with single 
(p=0.002) or aggregated (p=0.046) rMSCs. No effect of PFTBA incorporation was 
observed at any point in time. In contrast to BMP-2 release data, seeding of rMSCs 
considerably enriched the induction capacity of conditioned media on pre-osteoblast ALP 
activity (Figure 31B). Specifically, ALP activity for MC3T3-E1 cells treated with 
conditioned media from the first 24 hrs of construct culture was increased with rMSC-
seeding and PFTBA addition. At all timepoints, media conditioned by aggregate-seeded 
constructs were most effective to induce ALP activity. To determine whether changes in 
induction capacity were attributed solely to MC3T3-E1 number, ALP activity was 
normalized to DNA content. Normalized data continued to show a benefit of rMSC and 
PFTBA delivery, indicating that enhancement of ALP activity was not due to 
perturbation of MC3T3-E1 cell number alone. In all, these promising in vitro results 
further encouraged challenging of the rMSC aggregation strategy within a bone defect 





Figure 31: Effect of rMSC and PFTBA Delivery on In Vitro BMP-2 Release 
Acellular (Acell), single cell (SC), and aggregated (AG) rMSCs were embedded within 
alginate/mesh constructs with (+) or without (-) PFTBA and each containing a 1.5-µg 
dose of BMP-2. Constructs were cultured and conditioned media was collected over 7 
days. A) BMP-2 released from the constructs was measured via ELISA. Over the first 24 
hrs, all groups released similar amounts of BMP-2. However, following this initial 
period, acellular constructs released more BMP-2 than constructs seeded with single 
(p=0.002) or aggregated (p=0.046) rMSCs. There was no effect of PFTBA incorporation 
during either the first 24 hrs (p=0.143) or remaining (p=0.441) culture period. B) Despite 
BMP-2 release data, seeding of rMSCs led to increased induction of ALP activity in a 
pre-osteoblast cell line (MC3T3-E1) exposed to conditioned media. ALP activity was 
lower for acellular groups conditioned with media from the first 24 hrs in comparison to 
both rMSC-seeded groups (SC, AG). Media collected from aggregate-containing 
constructs at each timepoint induced ALP activity most strongly. Furthermore, PFTBA 
addition had an early positive effect (p=0.011). Normalized results indicate that changes 
in ALP activity were not due to altered MC3T3-E1 number alone. 
  
 113 
5.3.6 rMSC Aggregate Delivery for Bone Defect Repair in Lewis Rats 
 To examine the effect of rMSC aggregation on cell-based bone regeneration, 
bilateral femoral defects created in Lewis rats were treated with alginate/mesh constructs 
containing a 1.5-µg dose of BMP-2, seeded with no cells, single rMSCs, or aggregated 
rMSCs, and comprised of 0 or 10% PFTBA. The effect of syringe incubation, as is 
necessary to facilitate delivery of alginate-embedded rMSC throughout each surgical day, 
on cell viability was first examined. rMSCs embedded as single cells and aggregates 
remained viable following 0-, 4-, and 8-hr syringe incubations at 4°C (Figure 32). To 
assess whether syringe incubation or the incorporation of emulsion (+/- PFTBA) incurred 
a delayed detriment to cell viability, rMSC-seeded hydrogels were culture 48 hrs and 
evaluated via metabolic rate assay. Neither syringe incubation (p=0.170) nor addition of 











Figure 32: Viability of Alginate-Embedded rMSCs following Syringe Incubation 
Single cells and aggregates maintained viability (live = GFP (green); dead = ethidium 
homodimer (red)) following alginate embedding and syringe incubation at 4°C for 0, 4, 












Figure 33: Embedded rMSC Viability Across Segmental Defect Treatments In 
preparation for segmental defect delivery, all cell-seeded treatments (single cell vs. 
aggregates +/- PFTBA) were cultured over 2 days following syringe incubation of 0 or 8 
hrs at 4°C. Measurement using a metabolic rate assay indicated no adverse effect of 
syringe incubation (p=0.170) nor construct type (+/-PFTBA vs. alginate lacking 





 Following in vitro validation of pre-surgical rMSC viability, alginate/mesh 
treatments were delivered to critically-sized bone defects created in Lewis rats. 
Longitudinal radiographs captured at 4, 8, and 12 weeks post-operatively showed a 
qualitative decrease in bone regeneration with rMSC or PFTBA delivery (Figure 34). In 
fact, only injuries treated by acellular constructs lacking PFTBA (Acell-) demonstrated 
defect bridging. Treated femurs were explanted and analyzed via µCT and torsional 
testing at 12 weeks. Representative mineral density heatmaps were consistent with 
radiograph observations, showing a qualitative attenuation of bone repair with rMSC or 
PFTBA delivery (Figure 35). Quantification of regenerated bone tissue properties 
revealed that bone volume was greatest with Acell- treatment and that rMSC or PFTBA 
addition attenuated regenerated bone volume in both an individual and additive manner 
(Figure 36A). Mean density was increased with cell (p=0.025), but not PFTBA 
(p=0.172), delivery (Figure 36B). Connectivity density varied with treatment group 
similarly to regenerated bone volume, with the addition of rMSCs (p<0.001) or PFTBA 
(p=0.003) resulting in a measure decrease (Figure 36C). Functional restoration of tissue 
function was accomplished to the greatest extent with Acell- treatment, as assessed by 
measurement of maximum torque (Figure 37A) and torsional stiffness (Figure 37B). The 






Figure 34: Radiographs of Large Bone Defect Repair in Lewis Rats Representative 
radiographs of critically-sized femoral defects treated with acellular (Acell), single cell 
(SC), and aggregate (AG) containing hydrogels with (+) or without (-) PFTBA show a 
qualitative decrease in bone regeneration with rMSC or PFTBA delivery. By 12 weeks, 





Figure 35: µCT Reconstruction of Bone Defect Repair in Lewis Rats at 12 Weeks 
Representative mineral density heatmaps of the defect space and native bone ends were 
generated from µCT data. rMSC and PFTBA delivery appeared to qualitatively reduce 
the amount of mineral present in the defect space. Consistent with radiograph 





Figure 36: Properties of Regenerated Bone Tissue within Lewis Rat Defects A) 
Regenerated bone volume at 12 weeks was greatest for defects receiving acellular 
treatment lacking PFTBA (Acell-), as measured ex vivo via µCT. Treatment with rMSCs 
or PFTBA attenuated regenerated bone volume in both an individual and additive 
manner. B) Mean density exhibited an overall increase with cell (p=0.025), but not 
PFTBA (p=0.172), delivery. C) Connectivity density varied with treatment group 
similarly to regenerated bone volume, with the addition of rMSCs (p<0.001) or PFTBA 





Figure 37: Biomechanical Testing of Lewis Rat Defects at 12 Weeks A) Maximum 
torque was significantly increased with Acell- treatment compared to all other groups. 
Addition of rMSCs (pSC=0.001; pAG=0.001) or PFTBA (p=0.018) each promoted an 
overall decrease in torque. B) Torsional stiffness values were similar to maximum torque 
data, with Acell- treatment resulting in the highest value and an observed detrimental 
effect of rMSC (pSC=0.002; pAG<0.001) or PFTBA (p=0.024) addition. 
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 Tissue development within the defect space was examined histologically using a 
SafO stain and found to support µCT analysis (Figure 38). In the absence of rMSC or 
PFTBA delivery (Acell-), defects at 12 weeks contained organized bone tissue 
surrounding pieces of mineralized alginate. With the addition of cells or co-delivered 
PFTBA, mineralization within the injury space was qualitatively reduced and the 









Figure 38: Histological Examination of Lewis Rat Defects at 12 Weeks Tissue 
development within the defect space varied with rMSC and PFTBA delivery, as 
visualized via SafO staining. Injuries treated with acellular hydrogel in the absence of co-
delivered PFTBA (Acell-) contained the greatest extent of organized bone (blue) and 
mineralized alginate (pink) by 12 weeks. In contrast, delivery of rMSCs (singular (SC) or 
aggregated (AG)) or PFTBA (+) qualitatively decreased the extent of defect 




 Aggregation of MSCs is shown to engineer the cell secretome towards a pro-
angiogenic and anti-inflammatory mixture of factors. Due to the interplay of regenerating 
bone tissue with its inflammatory and vascular environment, MSC aggregation was 
pursued as an approach to augment cell-based bone defect repair (Mountziaris, Spicer et 
al. 2011, Chim, Tickner et al. 2013, Krishnan, Willett et al. 2014). Using an 
immunocompromised rodent model, the effect of hMSC aggregation on cell survival and 
construct vasculature was first explored via a subcutaneous implantation study. 
Subsequently, the capacity of delivered hMSC spheroids to facilitate low dose BMP-2-
mediated bone regeneration was evaluated within a critically-sized femoral defect. 
 hMSC aggregation produced comparable cell survival and construct vasculature 
when examined subcutaneously. Upon delivery to bone defects, hMSC single cell or 
aggregate delivery had no effect on regenerated bone volume or biomechanics in 
comparison to acellular treatment. However, within this animal model (Nude rats), 
biological variability was found to be a significant predictor of regenerative outcome. 
This finding motivated the continuation of aggregate delivery studies within a syngeneic 
animal model (Lewis rats). 
 In progression to the syngeneic model, in vitro characterization of rMSC spheroid 
immunomodulatory properties was first conducted. Consistent with hMSC findings, 
rMSC aggregation increased the secretion of IL-6 and PGE2 factors (Zimmermann and 
McDevitt 2014). Interestingly, aggregation also enhanced rMSC intracellular ALP 
activity. Although a known characteristic of MSC aggregates cultured under 
osteoinductive conditions, this had not previously investigated in the absence of 
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differentiation stimulus (Wang, Itaka et al. 2009, Frith, Thomson et al. 2010, Murphy, 
Fang et al. 2014, Yamaguchi, Ohno et al. 2014). Overall, similarities in the effect of MSC 
aggregation across cell species afforded pre-clinical relevance to testing spheroid delivery 
within the syngeneic rodent model.    
 In an effort to improve delivered rMSC survival, co-delivery of a synthetic 
oxygen carrier, PFTBA, was evaluated as well. Although perfluorocarbon addition to 
cell-seeded constructs has previously been shown to potentiate survival, our research did 
not observe this promotion of viable rMSC retention when tested under hypoxic culture 
or subcutaneously (Kimelman-Bleich, Pelled et al. 2009, Benjamin, Sheyn et al. 2013, 
Tamimi, Comeau et al. 2013). Given the extent of transport limitations imposed by our 
large volume alginate/mesh system, it’s possible that the limited effect of perfluorocarbon 
incorporation was indiscernible experimentally (Goh, Gross et al. 2010). Despite the lack 
of efficacy observed in these studies, PFTBA incorporation may potentially hold promise 
in the case of hMSC delivery. rMSCs may be more resistant to hypoxic-induced death in 
comparison to hMSCs due to interspecies variability in apoptotic mechanism (Reed, 
Doctor et al. 2003). Within our alginate system, rMSCs displayed qualitatively superior 
maintenance of cell viability following prolonged syringe incubation compared to 
hMSCs. Additionally, subcutaneous delivery of rMSC-seeded constructs achieved an in 
vivo survival of 6 - 40% through day 14, whereas the survival rate for hMSC-seeded 
constructs (hPL incorporation study samples included) was 1.5 - 2.5%. 
 Despite no effect on embedded rMSC number, PFTBA incorporation facilitated a 
short-term enhancement of osteoinductive factor release, as examined using an ALP 
induction assay performed on pre-osteoblasts. However, more striking augmentation of 
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osteoinductive factor release, in terms of effect size and timeframe, was achieved with 
embedded rMSC aggregates. This effect may be attributable to any number of secreted 
factors acting in isolation or synergistically to promote osteogenesis. rMSC spheroids 
exhibit increased fibroblast growth factor (FGF) and decreased dickkopf 1 (Dkk-1) 
production, each serving to facilitate osteoblast differentiation (Marie 2003, Fujita and 
Janz 2007, Zhang, Cho et al. 2008, Sart, Ma et al. 2014). Although enhanced expression 
of PGE2 and IL-6 motivated the evaluation of aggregation for MSC-based bone repair, 
the osteoinductive effect observed in this assay was likely not due to these anti-
inflammatory factors. IL-6 is shown to reduce ALP activity in the cell line studied here 
and PGE2 is considered to impact bone repair predominantly via immune cell signaling 
(Thomas and Puleo 2011, Kaneshiro, Ebina et al. 2014, Kovach, Dighe et al. 2015). In 
fact, similarly to IL-6 expression, aggregate-driven PGE2 signaling may have also acted 
counter to the observed effect, as increased PGE2 concentration is associated with a 
decrease in MC3T3-E1 ALP activity (Yokota, Kusaka et al. 1986, Suda, Tanaka et al. 
1998, Dey, Lejeune et al. 2006).  
 In spite of the promising osteogenic properties in vitro, delivery of rMSC-seeded 
treatments to a critically-sized bone defect attenuated BMP-2-mediated repair. This 
discrepancy may have been due to the more complex cellular environment present at the 
orthotopic injury site, an intricate milieu not captured in vitro. Possible explanations for 
the hindered bone repair with rMSC delivery include a reduction in the co-delivered 
BMP-2 available to endogenous cell populations, unfavorable effects of rMSC waste or 
death-associated factors, and adverse disruption of the post-injury inflammatory phase 
(Mountziaris and Mikos 2008, Dosier, Uhrig et al. 2015). In the absence of intervention, 
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bone regeneration proceeds through an initial inflammatory period which acts to engage a 
host of cell types at the site of injury, including the eventual recruitment of MSCs, and 
has proven essential to functional tissue restoration (Thomas and Puleo 2011). Although 
serving to position an osteoprogenitor cell type within the defect space, immediate 
delivery of MSCs could instead obstruct the early TNF-α and interleukin 1 (IL-1) 
signaling necessary for endogenous cell homing (Barnes, Kostenuik et al. 1999, 
Dimitriou, Tsiridis et al. 2005, Ortiz, Dutreil et al. 2007). 
 This presented research falls short of relating delivered rMSC survival to 
regenerative efficacy, as there is no evidence suggesting PFTBA incorporation or cell 
aggregation modulated cell survival within our delivery system. However, the effect of 
PFTBA treatment independent from rMSC-related outcomes was successfully isolated, 
finding that PFTBA addition to alginate/mesh constructs reduced bone regeneration 
irrespective of co-delivered rMSCs. PFTBA has previously been found to improve cell-
based mineralization, but had not been evaluated for its impact on acellular treatment 
strategy (Kimelman-Bleich, Pelled et al. 2009, Benjamin, Sheyn et al. 2013, Tamimi, 
Comeau et al. 2013). As PFTBA incorporation had no discernible effect on released 
BMP-2 quantity in vitro, we hypothesize that PFTBA-attenuated bone repair in vivo may 
have been due to differential release kinetics not captured by the in vitro timepoints 
selected or the consequence of modified alginate matrix properties, potentially perturbing 
the migration of endogenous cells into the defect region (White, Stoppel et al. 2013). 
 Overall, despite a multitude of in vitro evidence that MSC aggregation alters 
paracrine signaling, the present study observed no effect of spheroid delivery on cell-
based bone regeneration. Furthermore, MSC delivery was observed to attenuate BMP-2-
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mediated bone defect repair in comparison to acellular treatment. This latter finding was 
perhaps more unexpected, as several reports have demonstrated the efficacy of cell-based 
bone repair strategies in vivo (Ghantoji, Sail et al. 2010, Sheyn, Mizrahi et al. 2010, 
Dosier, Uhrig et al. 2015). We believe this discontinuity may be due to collective 
differences in the delivery vehicle (e.g. size and composition), stem cell type (e.g. source 
and extent of multipotency), and animal model (e.g. rodent strain and defect location) 
examined. In fact, previous work using alginate/mesh vehicles to induce ectopic 
mineralization identified a divergent effect of MSC delivery depending on cell source 
(Dosier, Uhrig et al. 2015). 
 This work highlighted the impact of animal model (immunocompromised vs. 
syngeneic) on the degree of biological variability present in a bone healing scenario. The 
effect of perfluorocarbon delivery on acellular BMP-2-mediated bone regeneration was 
also investigated which, to our knowledge, had not been previously pursued. Additional 
experiments, either through more sophisticated culture systems (e.g. co-culturing multiple 
cell types) or early timepoint analysis, are necessary to mechanistically probe the MSC- 
and PFTBA-attenuated bone repair observed in this study. 
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CHAPTER 6  CONCLUSIONS AND FUTURE DIRECTIONS  
 
6.1 Summary 
The objective of this research was to expose fundamental principles in developing 
an efficacious mesenchymal stem cell (MSC)-based therapeutic for the treatment of large 
bone defects. This effort was pursued through the investigation of two stem cell delivery 
strategies: utilization of platelet lysate (PL) and cell aggregation. The early and extensive 
death of stem cells following implantation is a well-established hurdle to development of 
volumetric tissue regeneration therapies. For this reason, we aimed to inspect the effect of 
MSC delivery strategy on implanted cell viability in addition to cell-based bone defect 
repair. Thus, our initial objective was the validation of a bioluminescent imaging (BLI) 
tracking protocol enabling the longitudinal monitoring of delivered MSCs in vivo. 
Using an immunocompromised rodent model, we developed a BLI technique 
capable of monitoring viable hMSC number through 1 week in vivo. Luciferase-labeled 
hMSCs were delivered within hydrogel/mesh constructs of large volume (>200 mm3), 
approaching the scale necessary to evaluate clinical applicability. Each hydrogel system 
tested, despite differences in signal magnitude, achieved a linear correlation between BLI 
signal and viable cell number immediately following implantation. Quantification of 
hMSCs present within alginate explants at 1 week using flow cytometry corroborated 
BLI data, demonstrating that a BLI signal vs. cell number correlation was retained, 
although of reduced correlative strength (r2=0.912 vs. r2=0.422). The observed decrease 
in correlation coefficient, suggestive of confounding variables present within the system, 
coincided with the development of contiguous fibrotic and vascular tissues. Overall, this 
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research developed an operational tool for the evaluation of cell-based delivery strategies 
while drawing attention to the potential impact of tissue development in its subsequent 
implementation. 
Following development and characterization of BLI technique, this tool was used 
to evaluate the potential of human platelet lysate (hPL) as a pre-treatment or co-delivery 
strategy for improved hMSC survival following implantation. Although culture in hPL 
media produced long-lasting hMSC expansion benefits in vitro, application prior to in 
vivo delivery elicited a reduction in delivered cell survival at 1 week. Incorporation of 
hPL within alginate/mesh constructs was also examined and observed to have no effect 
on the maintenance of hMSC viability through 14 days post-operatively. The utility of 
rodent models to serve as a pre-clinical testing stage for hPL co-delivery was 
subsequently examined. Potential limitations of the immunocompromised model were 
first investigated by studying the interaction between hPL and rMSCs, selected as a 
model host cell type. Exposure to hPL-supplemented media resulted in rMSC death, a 
process deemed attributable to heat labile proteins, but not due to membrane attack 
complex (MAC) formation. Next, the capacity of a syngeneic model to inform pre-
clinical decisions was examined through evaluation of interspecies variability for the PL 
product (hPL vs. rPL) and its effect on MSCs (hPL/hMSCs vs. rPL/rMSCs). The rodent 
system was found to be fundamentally distinct, with rPL having reduced growth factor 
content and stimulating no reduction in rMSC doubling time for the serum concentrations 
examined (5 and 10% v/v). 
The pursued hPL studies were motivated predominantly by an effort to enhance 
hMSC survival upon delivery. In an alternative strategy for improved cell-based bone 
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regeneration therapeutics, the effect of delivered cell function was explored through MSC 
aggregation, an approach shown to modulate hMSC paracrine signaling in vitro. When 
tested in a Nude rat subcutaneous implant model, hMSC aggregation achieved in vivo cell 
survival and construct vasculature comparable to that of delivered single cells. Through 
successive testing within a critically-sized bone defect, all BMP-2 containing treatment 
groups realized similar bone repair irrespective of whether they were seeded with 
singular, aggregated, or no hMSCs. However, biological variability was found to 
significantly predict regenerative outcome, a discovery that motivated further 
investigation of MSC aggregation using a syngeneic rodent model. rMSC aggregates 
were first characterized in vitro and shown to exhibit anti-inflammatory properties similar 
to that of hMSC aggregates. Consistent with the immunocompromised study, there was 
no effect of rMSC aggregation on cell survival or construct vasculature upon 
subcutaneous delivery. However, when combined with a low dose of BMP-2 (1.5 
µg/construct), aggregate-seeded alginate/mesh matrices showed encouraging results in 
vitro. Although incorporation of rMSC aggregates reduced the quantity of BMP-2 
released over 1 week in culture, the overall osteoinductive potential of construct-released 
factors was shown to increase, as assessed using a pre-osteoblast ALP induction assay. 
Yet despite this promising performance in vitro, delivery of rMSC-seeded vehicles 
attenuated functional regeneration in comparison to acellular treatment when challenged 
within the femoral defect model.  
This research aimed to elucidate fundamental principles for cell-based bone 
regeneration strategies through the investigation of hPL utilization and cell aggregation. 
Through this effort, the benefits and limitations of in vitro and rodent pre-clinical testbeds 
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were highlighted. Further attention was drawn to the selection of rodent strain in testing 
of biologic therapeutics (e.g. cells and blood-derived products). Using multiple 
implantation and in vivo monitoring techniques, survival and regenerative outcome 
measures were assessed for each MSC delivery strategy, serving to better understand how 
each variable may be perturbed and the extent of their interdependency within a large 
volume, cell delivery system. This work provides an experimental platform with which 
future cell-based therapeutic strategies could be tested. 
 
6.2 Future Directions for hPL Utilization 
 Although limitations of hPL pre-clinical testing were identified for both 
immunocompromised and syngeneic animal models, the utility of a co-delivery strategy 
could be further challenged using heat-inactivated hPL. Deactivation of the heat labile 
proteins responsible for rMSC death observed in vitro may lead to a more favorable 
interaction between rat host cells and the hPL-releasing construct. Additionally, the 
percentage of incorporated hPL could be increased from that examined in these studies in 
an effort to potentiate the treatment effect size. The 20% v/v concentration tested in this 
research was selected on the basis of (i) necessitation of a non-hPL hydrogel backbone 
(hMSC-seeded 100% v/v hPL hydrogels were contracted down to qualitatively negligible 
construct volume when cultured over 2 days in vitro) and (ii) ease in adaptation of our 
present syringe mixing protocol (during which 3% w/v alginate hydrogel is diluted down 
to 2%, limiting the added volume of all other components to 50 µL/construct). Our 
mixing protocol has since been adapted to accommodate the PBS/PFTBA emulsion 
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volume delivered for rMSC aggregates studies, thus the barrier to implanting a vehicle of 
higher hPL concentration has already been reduced.  
 While hPL pre-treatment showed no benefit in our studies, its application towards 
expansion of hMSCs for large volume tissue regeneration may still hold translational 
promise. The hMSCs delivered in this study were at low (3-4) passage. However, more 
pronounced effects of hPL vs. FBS culture have been noted for hMSCs at higher (10-11) 
passage (Griffiths, Baraniak et al. 2013). In a clinical setting, delivery of autologous 
hMSCs can require ex vivo expansion to moderately high passage in order to reach 
necessary cell number. Thus, in a clinically motivated study, the pre-treatment strategies 
presented here could be reassessed using hMSCs of higher (e.g. 5) passage to observe 
whether efficacy is achieved. 
 
6.3 Future Directions for MSC Aggregate Delivery 
 Despite the promising effect of rMSC-seeding, either as single or aggregated 
cells, on the osteoinductive capacity of construct-released factors in vitro, cell delivery 
went on to attenuate bone defect repair when challenged in vivo. Potential mechanisms 
for this include the engagement of alternative host cell populations (aside from the pre-
osteoblast phenotype tested in vitro) and rMSC-produced factors that act on this more 
complex range of endogenous cell types, potentially in a manner counterproductive to 
injury resolution. Further, it is likely that embedded rMSCs may have functioned 
differently within the in vivo environment due to differences in oxygen, nutrients, and 
waste transport as well as the existence of delivered vs. host cell cross-talk, distinct from 
the scenario of one-way communication tested in vitro. To probe the mechanism behind a 
 133 
lack of in vivo efficacy, the ALP induction in vitro experiment could be carried out under 
hypoxic or MC3T3-E1 co-culture conditions, two strategies aimed at better recapitulating 
the in vivo milieu.  Using this experimental design, the effect of delivery strategy on 
previously untested cell populations, including osteoblasts, osteoclasts, fibroblasts, and 
inflammatory cells, could also be explored. 
 Although we did not observe the immunomodulatory potential of MSC aggregates 
translating to enhanced bone repair, our studies took only one approach to investigating 
their effect on BMP-2-mediated regeneration. Rather than evaluating MSC aggregation 
for the improvement of low dose BMP-2 delivery, future work could explore the potential 
for MSC aggregates to mitigate the complications associated with high dose BMP-2 
treatment. Clinical application of BMP-2 often entails supra-physiologic dosing resulting 
in complications such as heterotopic bone formation and inflammation (Ratko, Belinson 
et al. 2010, Fu, Selph et al. 2013). Work in our lab has recently identified up-regulation 
of interferon gamma (IFN-γ) in the bone defect and adjacent muscle tissue (data not yet 
published) in response to high dose BMP-2 delivery. While MSCs have an inherent 
capacity to lower IFN-γ production from natural kill cells, this action is mediated by 
PGE2 and indoleamine 2,3-dioxygenase (IDO), two factors secreted in greater quantity 
with MSC aggregation (Spaggiari, Capobianco et al. 2008, Kode, Mukherjee et al. 2009, 
Zimmermann and McDevitt 2014).  
 
6.4 Discussion of Cell Delivery for Volumetric Tissue Regeneration 
 Cell delivery strategies for volumetric tissue regeneration face numerous hurdles. 
Ideally, delivery approaches would be targeted towards advancement of cell survival as 
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well as function, be this engineered secretion of factors or guided cell differentiation. In 
the presented research, each of these outcome measures was evaluated using a large 
volume alginate/mesh delivery system. However, a sequential approach to this research 
challenge could prove more fruitful. For example, delivery strategies could first be 
screened on the basis of implanted cell function by means of a small volume construct for 
which nutrient and waste transport is less limited. Successful approaches could then be 
scaled up in size to observe their impact on cell survival within these large volume 
systems. If maintained viability is found insufficient, efforts to augment it could be 
implemented through modulated design parameters. An iterative process using the small 
volume system to validate preservation of desired cell function with each added survival-
enhancing measure, followed by scale up to the large volume constructs, would constitute 
a logical workflow to isolate the collective potential of cell delivery techniques. 
One specific approach that could be tested in conjunction with hPL or aggregation 
strategies for the improvement of delivered MSC survival and facilitated regeneration is 
modification of the hydrogel carrier. While alginate hydrogel has proven to be an 
advantageous material for osteoinductive protein delivery, it may not be best suited for 
cell-based treatments. Alternative carriers used in tissue engineering applications include 
a spectrum of synthetic and naturally-derived scaffold materials. Additionally, these 
materials can be engineered through the manipulation of intrinsic properties of the pre-
existing backbone (e.g. structural properties) as well as the addition of controllable 
functional components (e.g. biological properties) (Lutolf and Hubbell 2005, Zhu 2010, 
Chan, Wippich et al. 2012). For example, functionalization of the poly(ethylene glycol) 
(PEG) synthetic hydrogel with the integrin-specific peptide GFOGER has been effective 
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to improve cell-based bone defect repair (Shekaran, Garcia et al. 2014). Alternatively, 
scaffolds sourced from mammalian, rather than plant, tissues could be investigated. Such 
matrices to be considered range from polymeric extracted proteins (e.g. collagen, gelatin, 
and fibrin) to native extracellular matrix (ECM) materials (e.g. amniotic membrane and 
small intestinal submucosa (SIS)) and represent highly attractive options due to their 
inherent bioactivity and amenability to remodeling by cells in vivo (Ruoslahti 2003, 
Erdbrugger, Konertz et al. 2006, Malafaya, Silva et al. 2007, Andree, Bar et al. 2013, 
Koob, Rennert et al. 2013, Murphy, McDevitt et al. 2014, Allen, Priddy et al. 2015). For 
example, use of a fibrin carrier has demonstrated efficacy of cell-based techniques for 
mineralized tissue formation within a variety of animal models (Sheyn, Kallai et al. 2011, 
Benjamin, Sheyn et al. 2013). Physical and biochemical cues of the biomaterial work in 
concert to drive embedded cell behavior including motility, proliferation, differentiation, 
and growth factor secretion (Marklein and Burdick 2010, Renth and Detamore 2012, 
Tejeda-Montes, Smith et al. 2012). Thus, despite the intrinsic functionality of naturally-
derived mammalian materials in their raw form, structural and biofunctional 
augmentation techniques for these matrices have been explored in an effort to further 
cell-based regenerative potential (Haghi and Akbari 2007, Malafaya, Silva et al. 2007, 
Renth and Detamore 2012, Bajaj, Schweller et al. 2014, Allen, Priddy et al. 2015). 
Approaches including the use of composite materials, manipulation of mechanical 
properties, and addition of heparin-binding domains (HBD) or enzymatically cleavable 
sequences have demonstrated efficacy in modulating embedded cell function and 
facilitating cell-based bone tissue engineering (Engler, Sen et al. 2006, Choi, Lee et al. 
2010, Fu, Wang et al. 2010, Feng, Zhu et al. 2014, Inzana, Olvera et al. 2014, Levato, 
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Visser et al. 2014). Overall, the investigatory space of carrier systems that may serve to 
potentiate cell-based bone regeneration is great and worthy of exploration. 
 Alternate or complementary to modifying the hydrogel carrier, implementation of 
construct pre-vascularization or addition of vascular constituents pre-implantation could 
be pursued. Efforts to accelerate early vascularization of large volume constructs have 
taken many forms, including the addition of vascular components (e.g. cells and vessel 
fragments) which have demonstrated the ability to inosculate with host vasculature 
following implantation (Rouwkema, Rivron et al. 2008, Zhou, Zhou et al. 2010, Novosel, 
Kleinhans et al. 2011, Laschke and Menger 2012, Krishnan, Chang et al. 2013, 
McFadden, Duffy et al. 2013). Such techniques aimed to improve early vascularization 
may prove effective for potentiating delivered cell survival within our alginate/mesh 
delivery system and potentially enable the benefit of hPL or aggregation strategies to be 
realized.  
 While efforts to enhance early construct vasculature may improve delivered cell 
survival, it should be noted that these system variables are unlikely to change in isolation. 
Work validating the BLI tracking protocol observed alteration of BLI profile contiguous 
with construct tissue development. Construct material properties, such as stiffness, have 
also been found to change with promotion of construct vasculature (Krishnan, Hoying et 
al. 2007). Interdependency of these therapeutic characteristics should not be overlooked, 
as construct vasculature could potentially be modified even in the absence of focused 
manipulation; for example, in selection of an animal model. Restructuring data from this 
thesis work to evaluate construct vascular volume as a function of delivered MSC 
species/strain (human, Lewis rat, or Sprague Dawley rat) and rodent model (Nude, Lewis, 
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or Sprague Dawley rat), there was no effect of the immunocompromised (n=53) vs. 
syngeneic (n=28) delivery on vascularization (Figure 39). However, seeding of constructs 
with Sprague Dawley-derived rMSCs may undergo strain-specific vascularization. As the 
sample size for these groups was small (n=4), further studies are necessary to determine 







Figure 39: Construct Vascular Volume by Animal Model Construct vascular volume 
across all alginate/mesh subcutaneous MSC delivery samples presented in this thesis 
(hPL pre-treatment, hPL co-delivery, and single cell vs. aggregates studies) was not 
observed to differ as a function of immunocompromised (hMSC à Nude) or syngeneic 
(Lewis à Lewis) rodent model. However, delivery of Sprague Dawley (SD) rMSCs may 
promote construct vasculature in a rodent strain dependent manner (n=4). As each 
treatment was examined within a single animal, a larger sample size is needed to 
determine whether this is a representative effect of treatment or due to biological 






























6.5 Final Conclusions and Significance 
 We conclude that, while BLI may prove advantageous for informing large volume 
cell-based therapeutic design, care should be taken when implementing and drawing 
quantitative conclusions using this assessment technique. Furthermore, this thesis work 
highlights that two hydrogels of relatively similar material properties can exhibit 
divergent behavior under bioluminescent analysis. Overall, validation of BLI protocol 
and investigation of potentially confounding variables, such as vascular ingrowth and 
fibrosis, should be conducted on a system-by-system basis in order to draw representative 
conclusions in future analyses.  
 Although hPL utilization and MSC aggregation did not prove advantageous for 
maintenance of cell survival or facilitated bone regeneration in this body of work, these 
strategies may be efficacious in alternate, and perhaps more clinically relevant, delivery 
scenarios. As mentioned, hPL utilization could be investigated for improved high passage 
MSC delivery and a future direction of MSC aggregation may be to preclude high dose 
BMP-2 complications. 
 Importantly, this presented work draws attention to the critical task of animal 
model selection in developing a cell-based regenerative therapeutic. Both 
immunocompromised and syngeneic systems are with distinct benefits and limitations. It 
is necessary to acknowledge the utilities of each and select a model based on this 
knowledge. In the case of evaluating MSC-based delivery strategies, the extent of 
“immunological privilege” afforded to this cell type should not be overstated (Ankrum, 
Ong et al. 2014). Although dramatic hMSC death was observed in many of the presented 
experiments, viable delivered cells were consistently detectable through the study 
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conclusion (7 or 14 days) when delivered to Nude rats. In contrast, a pilot study 
conducted in Lewis rats detected no signal from GFP/Luc hMSCs past 5 and 7 days for 
aggregated and singular hMSCs, respectively (data not shown). Thus, challenging hMSC 
delivery approaches within an immunocompetent animal model is not a viable testbed for 
strategies aimed at achieving long-term cell survival. 
 Ultimately, the best approach for evaluating cell-based bone regeneration 
techniques may be the use of multiple rodent animal models. In addition to revealing the 
robustness of therapeutic strategy through evaluation within multiple test systems, 
dissimilarities in efficacy may provide valuable insight into therapeutic mechanism. 
Furthermore, recent studies have highlighted the meager reproducibility of published 
biomedical findings (Prinz, Schlange et al. 2011, Begley and Ellis 2012). Examination of 
a promising phenomenon within multiple animal models may confirm its fortitude and, 
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